

Oncological management and pregnancy outcomes in women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients.

Jorine de Haan MD^{a,b*}, Magali Verheecke MD^{a,c*}, Kristel Van Calsteren PhD^{d,e}, Ben Van Calster PhD^e, Roman G. Shmakov PhD^f, Mina Mhallem Gziri PhD^g, Michael J. Halaska PhD^h, Robert Fruscio PhDⁱ, Christianne A.R. Lok PhD^j, Ingrid A. Boere PhD^k, Paolo Zola PhD^l, Petronella B. Ottevanger PhD^m, Prof. Christianne J.M. de Groot PhD^b, Fedro A. Peccatori PhDⁿ, Karina Dahl Steffensen PhD^{o,p}, Prof. Elyce H. Cardonick PhD^q, Evgeniya Polushkina PhD^f, Prof. Lukas Rob PhD^h, Lorenzo Ceppi MDⁱ, Prof. Gennady T. Sukhikh PhD^f, Sileny N. Han PhD^{a,c}, Prof. Frédéric Amant PhD^{a,c,j,f}. *On behalf of the International Network on Cancer, Infertility and Pregnancy (INCIP).*

* Equal contribution.

a Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium

b Department of Obstetrics and Gynaecology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

c Division of Gynaecologic Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium

d Department of Obstetrics and Gynaecology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.

e Department of Development and Regeneration, KU Leuven, Herestraat 49 box 805, 3000 Leuven, Belgium

f Federal State Budget Institution "Research Center for Obstetrics, Gynecology and Perinatology", Ministry of Healthcare of the Russian Federation, 4 Oparina street, Moscow 117997, Russian Federation

g Department of Obstetrics, Cliniques Universitaires St. Luc, UCL, Hippokrateslaan 10, 1200 Sint-Lambrechts-Woluwe, Belgium

h Faculty Hospital Kralovske Vinohrady and 3rd Medical Faculty, Charles University, Srobarova 1150/50, Prague 10, 100 34, Czech Republic

i Clinic of Obstetrics and Gynecology, University of Milan Bicocca, San Gerardo Hospital, Via G.B. Pergolesi, 33, 20900 Monza, Italy

j Center for Gynaecologic Oncology Amsterdam, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands

k Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 's Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands

l Department of Surgical Sciences, University of Turin, Via Giuseppe Verdi 8, 10124 Turin, Italy

m Department of Medical Oncology, Radboud University Nijmegen Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands

POSTPRINT VERSION

n Division of Gynaecologic Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

o Department of Oncology, Vejle Hospital, Beriderbakken 4, DK-7100, Vejle, Denmark

p Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Winsløwparken 19-3, DK-5000 Odense C, Denmark

q Department of Obstetrics and Gynaecology, Cooper University Health Care, 1 Cooper Plaza, Camden, NJ 08103, the United States of America

r Centre for Gynaecologic Oncology Amsterdam, Academical Medical Center Amsterdam, the Netherlands

Corresponding author:

Frédéric Amant, MD, PhD

Center for Gynaecologic Oncology Amsterdam

Antoni van Leeuwenhoek - Netherlands Cancer Institute

Plesmanlaan 121

1066 CX Amsterdam

The Netherlands

Email: f.amant@nki.nl

Phone: +31 20 512 29 75

Abstract

Background

The effect of the increased awareness of the potential to treat cancer during pregnancy is currently unknown. The International Network on Cancer, Infertility and Pregnancy (INCIP) registers the incidence and maternal, obstetrical, oncological and neonatal outcome of cancer occurring during pregnancy. In this INCIP study, we aimed to describe the oncological management and the obstetrical and neonatal outcomes of patients treated in the last 20 years and evaluate their changes over time. Further, we evaluated associations of malignancy type and treatment with obstetrical and neonatal outcomes.

Methods

This descriptive cohort study involved data from pregnant patients with cancer registered by all 37 centres (from 16 countries) participating in the INCIP registry. Oncological, obstetrical and neonatal outcome data of consecutive patients diagnosed with primary invasive cancer during pregnancy between 1996 and 2016 were retrospectively and prospectively collected. We analysed changes over time with log-binomial regression. We used multiple logistic regression to analyse preterm pre-labour rupture of membranes (PPROM) and/or contractions, small for gestational age (SGA), and neonatal intensive care unit (NICU) admission. In these models, malignancy type, six chemotherapeutic agents (alkylating, anthracyclines, antimetabolite, taxanes, platinum, and any other agent), and abdominal and/or cervical surgery were the key covariates, prespecified confounding variables were time period of diagnosis, age at diagnosis, diagnosis in 3rd pregnancy trimester, and systemic disease. The INCIP registry is registered with ClinicalTrials.gov (NCT00330447), and is ongoing.

Findings

1170 patients were included. Breast cancer was the most common malignancy (n=462, 39%). 779 patients (67%) received treatment during pregnancy. Every five calendar years, treatment during pregnancy increased by 10% (95% CI 5 to 15). This increase was mainly related to an increase of chemotherapeutic treatment by 31% every five calendar years (95% CI 20 to 43). Overall, 995/1089 singleton pregnancies ended in a live birth (88%) of which 429 (48%) ended preterm. Every five calendar years, 4% more live births (95% CI 1 to 6), and 9% less iatrogenic preterm deliveries (95% CI 2 to 16) were reported. Our data suggested a relationship between platinum-based chemotherapy and SGA (odds ratio 3.12, 95% CI 1.45 to 6.70), and between taxanes and NICU admission (odds ratio 2.37, 95% CI 1.31 to 4.28). NICU admission was suggested to depend on malignancy type, with gastro-

POSTPRINT VERSION

intestinal cancers having highest risk (odds ratio vs. breast cancer 7·13, 95% CI 2·86 to 17·7) and thyroid cancers having lowest risk (odds ratio vs. breast cancer 0·14, 95% CI 0·02 to 0·90). Unexpectedly, the data suggested that abdominal and/or cervical surgery was related to a lower NICU admission rate (odds ratio 0·30, 95% CI 0·17 to 0·55). Other associations of treatment and malignancy type were less clear.

Interpretation

Over the years, we observed that more patients with cancer during pregnancy received antenatal treatment, especially chemotherapy. Our data indicate that patients with antenatal chemotherapy exposure may have an increased risk to develop pregnancy related complications, specifically SGA and NICU admission. We therefore recommended involving hospitals with obstetrical high care units in the management of these patients.

Funding

Research Foundation-Flanders, European Research Council, Charles University, Ministry of Health of the Czech Republic.

Introduction

Based on several national-wide studies, the incidence of cancer during pregnancy is estimated to be one in 1000 pregnancies.¹⁻³ Breast cancer, haematological cancer, cervical cancer and melanoma are the most commonly diagnosed malignancies during pregnancy.^{4,5} Awareness of this subject has increased the number of cohort studies on maternal and foetal outcome in these women.^{4,5} These studies focused on overall maternal and obstetrical outcome, but their population size or follow-up is limited.

In 2010, our group published the first epidemiologic data on cancer during pregnancy based on the registry of the International Network on Cancer, Infertility and Pregnancy (INCIP).⁴ Few years later, Amant et al.^{6,7} published two prospective follow-up studies of children with antenatal chemotherapy exposure. They found no clinical difference in neurocognitive and cardiac development between the treatment and the control group. In both groups, preterm delivery was the main risk factor for paediatric developmental problems up to three years of age.⁷ These studies showed reassuring results on the neonatal and infant outcome up to three years and strengthened the overall idea that oncological treatment in pregnancy is feasible. However, the effect of antenatal chemotherapy on secondary malignancies or fertility later in life is still not known. Antenatal exposure to cancer treatment, and especially chemotherapy, was associated with a higher proportion of small-for-gestational-age (SGA) children in some studies,^{4,6,8,9} while others did not find such an association.^{2,10} Also, several studies described an increased preterm delivery rate in patients with cancer during pregnancy.^{2,4,8} Nevertheless, these studies were often small and could not identify which patients with cancer in pregnancy are at risk for negative obstetrical or neonatal outcome.

The aim of this study is to describe the oncological, obstetrical and neonatal data of the INCIP registry and to evaluate changes in obstetrical management and neonatal outcome over the last 20 years. We hypothesized that over the years more patients were treated during pregnancy, which might have influenced the obstetrical and/or neonatal outcome. Further, we investigated whether type of malignancy or treatment modalities might be related to adverse obstetrical or neonatal outcomes within the group of patients with cancer during pregnancy. We hypothesized that chemotherapy during pregnancy might have resulted in a higher number of adverse outcomes. We were particularly interested in the following outcome measures because they were relatively common: preterm prelabour rupture of membranes (PPROM) and/or preterm contractions, SGA and neonatal intensive care unit (NICU) admission. See Appendix, page 3.

Methods

Study design and patients

This was a descriptive cohort study that involves data from pregnant patients with cancer registered by all 37 centres (16 countries) participating in the INCIP registry. The INCIP was established in 2005 to evaluate oncological care and obstetrical, maternal and neonatal outcome in women with cancer during pregnancy (www.cancerinpregnancy.org). The aim was to register consecutive patients both retrospectively and prospectively. Before 2005, all patients were included retrospectively, after 2005 it depended on the date on which a centre started participating to our study. To include retrospective patients in a most consecutive order, hospitals used patient databases to identify all eligible patients within their hospital. Patient data were registered upon written informed consent of the patients. This study was approved by the Ethical Committee of University Hospital Leuven (Belgian number B322201421061).

Patients diagnosed between 01/01/1996 and 10/18/2016 with primary invasive cancer and borderline ovarian cancer during pregnancy, were eligible. Patients with pre-invasive disease or postpartum diagnosis were excluded. Detailed oncologic, obstetric and neonatal data were collected. Diagnosis was made using local standards, but all included histopathological confirmation. We divided our cohort in 3 subgroups according to year of diagnosis: 1996-2004 (group 1); 2005-2009 (group 2); 2010 - November 2016 (group 3). The differentiation between group 1 and 2 was based on the start of our online registration study in 2005, after which most registrations were prospective. The differentiation between group 2 and 3 was based on the publication date of the first INCIP report.

Systemic disease was defined as TNM or FIGO stage IV disease and leukaemia, non-systemic disease was defined as TNM or FIGO stage I to III and all brain cancers. For the variable 'surgery during pregnancy', we only included therapeutic surgical procedures. PPRM was assessed following local protocol and was defined as preterm rupture of membranes without contractions. Perinatal mortality was defined according to the WHO guidelines as the number of stillbirths and deaths in the first week after birth. Major and minor congenital malformations were defined according to Eurocat (www.eurocat-network.eu). Birthweight percentiles were calculated according to the percentile calculator from www.gestation.net (v6.7.5.7(NL), 2014). The included parameters are shown in the Appendix, page 4. Birthweight below the 10th percentile was considered as SGA.

This study is registered as an International Observational Cohort study with ClinicalTrials.gov (NCT00330447) and approval was obtained from all participating centres and authorities. See

<http://www.cancerinpregnancy.org/study-protocols> for the full study protocol, this manuscript is based on study part I and the primary objective of this study lies within the wider primary objective of the study protocol.

Statistical analysis

No dedicated sample size calculation was performed for this descriptive study. We agreed upon an analysis strategy beforehand, did not adapt this strategy based on obtained results, and fully reported all results. We provide descriptive statistics of oncological, obstetrical, and neonatal information. Then, we analysed the relationship of malignancy type and treatment modalities with obstetrical and neonatal outcomes (PPROM and/or preterm contractions, SGA, and NICU admission) with multiple logistic regression models using Firth bias correction. We stress that these models do not include a control group of patients without cancer, but compare patients with cancer during pregnancy with respect to the presence or absence of different characteristics or exposures. For the obstetrical outcome PPRM and/or preterm contractions, we based the regression analysis on the sample of singleton live births and stillbirths. For the two neonatal outcomes, we based the analysis on the sample of singleton live births only. Both outcome variables and covariates in the models were fully pre-specified. Key covariates in the models were malignancy type, six chemotherapeutic agents (alkylating, anthracyclines, antimetabolite, taxanes, platinum, and any other agent), and abdominal and/or cervical surgery. We added the following potential confounding variables without further data-driven variable selection: time period of diagnosis, age at diagnosis, diagnosis in 3rd pregnancy trimester, and systemic disease. We did not consider interaction terms. Alkylating chemotherapeutic agents were divided into platinum and other alkylating agents due to the relatively higher placenta passage of carboplatin compared to other agents in baboon models and the high placental passage of cisplatin in humans.^{11,12} We reported adjusted odds ratios (OR) with 95% confidence intervals (CI) from the multiple logistic regression models. We report p-values to measure the strength of the evidence against the null hypothesis of no relationship, but do not specify an alpha level and hence do not determine statistical significance. For the multiple regression models, we handled missing values for covariates or outcomes using multiple imputation (See Appendix, page 5).¹³ As a sensitivity analysis, we compared results based on imputed data with results based on complete case analysis.

For the descriptive analysis and evaluation of changes over 20 years in categorical patient characteristics, outcomes, and treatment modalities, we use univariable log-binomial regression models with year of diagnosis as a continuous predictor. We express results using relative risks (RR) to describe the average change every five calendar years (See Appendix, page 6), together with 95% confidence intervals. For continuous parameters, we

use univariable linear regression with year of diagnosis as continuous predictor, with results expressed as average change every five calendar years. Statistical significance was not determined. For this analysis, we did not impute missing data but rather used available cases. This analysis was prespecified, and was performed and reported for all parameters of interest.

The analysis was performed using R 3.3.1 (www.r-project.org).

Role of the funding source

The financial funders had no role in the study design, data collection, data analysis, interpretation of the data or in writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

The trial design is depicted in Figure 1. In total, 1170 consecutive patients were eligible from 37 centres in 16 countries. The distribution of countries with highest accrual was as follows: Belgium (319, 27%), the Netherlands (278, 24%), Italy (179, 15%), Russia (135, 12%) and Czech Republic (100, 9%). Specifications of inclusion are in Appendix, page 7 and 8. An overview of missing values is given in Appendix, page 9 and 10).

Oncological information

Baseline characteristics are shown in Table 1, distribution of malignancies and stage of disease per malignancy are depicted in Figure 2A and 2B, respectively. Seventy-nine percent (893/1125) of patients had non-systemic disease. Forty-five percent (n=490/1098) of patients were diagnosed in the second trimester, whereas 24% in first and 24% in third trimester (Appendix, page 11 for specification per malignancy).

Of all 1170 patients, 779 (67%) received treatment during pregnancy, of which 574 received a single treatment modality (74%) and 205 a combination of different treatment modalities (26%) (Table 2; Appendix, page 12). Surgery was the most common therapy in patients with thyroid cancer, ovarian cancer or melanoma. Chemotherapy was the most common treatment modality in patients with lymphoma or breast cancer. The majority of patients with cervical or brain cancer were not treated during pregnancy (respectively 56% and 52%). Specification of the different chemotherapeutic agents given during pregnancy can be found in Table 1. Combination regimens consisting of more than one chemotherapeutic agent were registered in 351/423 (83%) patients. Abdominal and/or

cervical surgery was performed in 149 patients. Sixty-nine percent (98/143) of these patients had stage I disease and for 70% (104/149) surgery was the only treatment modality performed during pregnancy.

Obstetrical information

Of all 1142 pregnancies with known obstetrical outcome, 25 (2%) ended in a miscarriage and 113 (10%) were terminated. Sixty-two percent (64/103) of terminations were performed in the first trimester, 38% (n=39/103) in the second trimester. For 10 patients, GA at termination was unknown. Main reasons for termination were start of oncological treatment or poor maternal prognosis (77%), unwanted pregnancy (10%), and foetal anomalies (4%). Information on differences in number of terminations per period of diagnosis and malignancy type can be found in Appendix, page 13. Of the ongoing pregnancies, there were 27 twin pregnancies and 1 triplet pregnancy. Five (<1%) patients died during pregnancy. For the obstetrical outcomes, only data from singleton live births and stillbirths are reported and is summarized in Table 3.

Of the 969 ongoing singleton pregnancies, seven (1%) intra-uterine fetal deaths and seven (1%) perinatal deaths were reported, see Appendix, page 14 for detailed information on these cases. All other 955 pregnancies (99%) ended in a live birth. Preterm delivery rate was 48% (429/887, excluding 68 cases with missing GA at birth). Eighty-eight percent (373/425) of preterm deliveries was iatrogenic. PPRM and/or preterm contractions (98/969, 10%) was the most reported obstetrical complication (Appendix, page 15). From all these patients, 52 patients actually delivered spontaneously before 37 weeks (53%).

Neonatal outcome

For neonatal outcomes, only data from singleton live births are reported. Percentages of missing data in singleton live births are presented in Appendix, page 16. Birth weight percentiles were calculated in 796/955 (83%) singleton live births for which birth weight and GA at delivery were known (Appendix, page 16). Data on all neonatal outcomes stratified by different variables are shown in Appendix, page 17. 167/796 children (21%) were SGA. Information on neonatal intensive care unit (NICU) admission was available for 720/955 (75%) children, with an admission rate of 41% (298/720). NICU admission was mainly prematurity related (249/298, 84%). The presence of congenital malformations was reported in 32/721 (4%) live born singletons, with 17 (2%) minor and 15 (2%) major malformations (2.5-3% major malformations are reported in general population¹⁴). Three other pregnancies were terminated because of foetal anomalies (hydrocephalus, trisomy 21 and unspecified major malformations). Anomalies did not differ between the different treatment modalities. (Appendix, page 19)

Association of malignancy type and treatment modalities with adverse obstetrical or neonatal outcomes

Here we describe results for the key variables (malignancy type, administration of chemotherapeutic agents, and abdominal and/or cervical surgery). Full results of the multiple logistic regression models, including associations for the prespecified potential confounders (age at diagnosis, period of diagnosis, trimester at diagnosis, and systemic disease), can be found in Table 4. Model coefficients and standard errors can be found in the Appendix, page 20.

The multiple regression model for SGA provided support for a relationship between chemotherapy and SGA, in particular for platinum-based chemotherapy (OR 3.12, 95% CI 1.45-6.70). Other agents like non-platinum alkylating chemotherapy or taxanes may also be related (OR>2), but results were more uncertain. Malignancy type and abdominal and/or cervical surgery had a weak relation with SGA (Table 4; Appendix page 21).

For NICU admission, there appears to be a strong independent association with malignancy type: gastro-intestinal cancers had the highest admission rates (OR 7.13 vs. breast cancer, 95% CI 2.86-17.7), thyroid cancer to the lowest (OR 0.14 vs. breast cancer, 95% CI 0.02-0.90) (Appendix page 22). There was again support for an association between chemotherapy and NICU admission, in particular for taxanes (OR 2.37, 95% CI 1.31-4.28). Finally, the data suggested that abdominal and/or cervical surgery was related to a lower NICU admission rate (OR 0.30, 95% CI 0.17-0.55).

For PPRM, the least common of the three investigated complications with 98 registered instances, results were largely inconclusive for all variables (Table 4; Appendix page 23). This was the least common of the investigated outcomes, resulting in high standard errors (Appendix, page 20). The relationship between chemotherapy and PPRM is in line with our hypothesis, with OR>2 for the platinum and non-platinum based alkylating agents.

The sensitivity analysis based on complete cases provided highly similar results (Appendix, page 24).

Changes over 20 years

Specification of descriptive statistics per time period, and analysis of change over time is given in Appendix page 25. An overview of the most important changes per period can be found in Figure 3. Every five calendar years, there was an increase of 10% in the number patients who received treatment during pregnancy (RR 1.10, 95% CI 1.05 to 1.15). Also, every five years, 31% more patients received chemotherapy during pregnancy (RR 1.31, 95% CI 1.20 to 1.43), and only 1% less patients underwent surgery (RR 0.99, 95% CI 0.92 to 1.07).

Radiotherapy became less frequent and targeted therapy more frequent, but these modalities were uncommon in general. Every five years, we observed an increase of 2.6 days (95% CI -1.1 to 6.3) in the GA of the last chemotherapy cycle given during pregnancy.

Every five years, there were 4% more live births among singletons (RR 1.04, 95% CI 1.01 to 1.06), 7% fewer preterm live births (RR 0.93, 95% CI 0.86 to 0.99), and 9% fewer iatrogenic preterm live births (RR 0.91, 95% CI 0.84 to 0.98). In line with the declining number of preterm deliveries, every five years, NICU admissions decreased with 9% every five years (RR 0.91, 95% CI 0.83 to 0.99). The occurrence of SGA increased 16% every five years (RR 1.16, 95% CI 0.99 to 1.35). We observed a 3% decrease in PPROM and/or preterm contractions every five years (RR 0.97, 95% CI 0.80 to 1.18).

Discussion

Our data suggested a relationship between platinum-based chemotherapy and SGA, and between taxanes and NICU admission. NICU admission was suggested to depend on malignancy type. Unexpectedly, the data suggested that abdominal and/or cervical surgery was related to a lower NICU admission rate. Other associations of treatment and malignancy type were less clear. Over 20 years, we observed an increased number of pregnancies ending in a live birth that coincide with cancer together with an increase of 31% every five years in patients treated with chemotherapy during pregnancy (Appendix, page 25). In line with the increasing chemotherapy rates over the years, SGA also increased with 16% every five calendar years. These results strengthen the recommendation to involve hospitals with obstetrical high care units in the management of pregnant cancer patients with these risk factors. The complexity of dealing with two patients at once stresses the need for a multidisciplinary approach.

The reason for the observed increased rate of chemotherapy during pregnancy in combination with an increase of live births may be attributed to changing treatment regimens during the period of registration in combination with reassuring results on antenatal chemotherapy exposure. Since 1996, 25 cohort studies including more than 50 patients were published on the subject of cancer during pregnancy with a focus on obstetrical outcome (Appendix, page 26). In summary, a high rate of preterm birth was observed, but the relation between SGA and cancer treatment during pregnancy remained inconclusive. Several studies describe a reassuring foetal outcome after chemotherapy during pregnancy. No congenital, neurologic or psychologic abnormalities were detected in children antenatal exposed to chemotherapy.^{7,15,16} These reassuring fetal, neonatal and infant outcome up to three years,

together with the similar maternal survival rates compared to non-pregnant women diagnosed and treated for cancer, are potential factors for the increase of cancer treatment over time as observed in our analysis.

The current study confirms the high overall prematurity rate (48%) in patients with cancer during pregnancy, as published by several previous cohort studies (Appendix, page 26). Preterm birth is related to an increased risk of perinatal morbidity and mortality, and neurodevelopmental impairment later in life. There is a direct correlation between a lower GA at delivery and negative outcome.¹⁷ Lu et al.⁸ observed an increased risk of neonatal mortality in patients with cancer during pregnancy (IRR 2.7, 95% CI 1.3 to 5.6), which was caused by prematurity in 89% of the cases. Our study found inconclusive results on the association between antenatal chemotherapy exposure and PPROM and/or contractions. As for other risk factors for spontaneous premature delivery, we hypothesised that patients undergoing abdominal and/or cervical surgery would be at greater risk of PPROM and/or preterm contractions. Our multiple regression analysis did not support such an effect. It may be explained by the high number of stage I disease (69%) and surgical therapy only (70%) in this group of patients, as these patients have no potential risk factors for adverse obstetrical or neonatal outcome.^{18,19} We observed a decline of the preterm birth rate during the registration period of 7% every five calendar years, which was mainly attributed to the lower iatrogenic prematurity rate. This decline may be attributed to the tendency to continue chemotherapy longer during pregnancy to postpone delivery for the benefit of the child. Although, we realize that the effect of 2.6 days (95% CI -1.1 to 6.3) every five years is not strong. This may be explained by the fact that reassuring results on antenatal chemotherapy were published only a few years ago and that the follow-up in this cohort is not long enough to fully evaluate this change.

The tendency to treat more patients with chemotherapy during pregnancy may also have adverse consequences. We reported an increased incidence of SGA. Preterm birth, perinatal morbidity and mortality in the first weeks and cardiovascular and metabolic diseases later in life are more frequently seen in these children.^{20,21} Several studies have highlighted an increased rate of SGA in children from patients with cancer during pregnancy (Appendix, page 26). Still, influences of supportive medication, stress and malnutrition cannot be excluded.

We hypothesized a relationship between systemic disease and SGA, for which our analysis provided mild support. In these patients, nutritional state besides other factors, such as general condition, fatigue and circulating cytokines, may be compromised compared to patients with localized malignancy, irrespective of the treatment given.

Our study further suggests a relationship between chemotherapy, mainly platinum-based agents, and SGA, as hypothesized. Several reasons may contribute to such a relationship. Chemotherapeutic agents have several toxic properties of which some cause direct damage to the DNA or interfere with DNA replications (e.g. alkylating

agents, antimetabolites). These direct DNA damage might influence the placental development and its blood supply towards the fetus. Additional indirect effects of chemotherapy (induction of vasculopathy or inflammation), or the maternal illness itself (associated with malnutrition, anaemia, and high maternal stress) may further contribute to restricted foetal growth.²²⁻²⁴ Besides the impact of chemotherapy on foetal growth, the maternal age has an additional impact, but also influences of supportive medication, stress and malnutrition can be contributively. Fortunately, the lower birth weights in chemotherapy-exposed children recover, with normal values for weight, height, and head circumference in the first months of childhood.^{6,7}

In pregnant patients with cancer, it is important to recognize obstetrical and neonatal risks associated with cancer and its treatment modalities. The tendency to avoid preterm deliveries by cancer treatment during pregnancy needs to be balanced against an increased risk of SGA children. The short- and long-term risks of SGA are important to consider, nevertheless the risk of preterm birth is also of great importance. More long-term research comparing the risks in these two groups is necessary.

To our knowledge, this cohort is the largest cohort on cancer in pregnancy. This study adds to the identification of patients at high risk for obstetrical and neonatal complications. However, limitations to this study need to be addressed. First, we observed missing data for the neonatal outcomes. This can be attributed to the participating hospitals, of which some are either specialized in oncology or obstetrics and perinatology, leading to lack of either oncological or obstetrical and neonatal information. Due to the necessity to report obstetrical complications when observed, but no explicit mention of the absence of complications, it is possible that the occurrence of obstetrical complications is underreported. Second, since we only documented sampling data from our online database registered on a voluntary basis by the participating centres of INCIP including retrospectively included cases, the incidences of the different tumour types and percentages of the treatment modalities given during pregnancy may also differ from these in the worldwide pregnant population. Although all participating centres however acknowledged to have registered all their consecutive cases rigorously, some selection bias for retrospectively included cases cannot be excluded. Third, a common issue in observational studies is the presence of confounding, in our case between treatment and patient or tumour characteristics. Fourth, due to the rarity of cancer in pregnancy and the changes in cancer treatment over the last years, we encountered small group sizes for some malignancies and treatment modalities of which subgroup analysis was not possible.

The observation of increased SGA with chemotherapy exposure needs further research. In our study percentiles were calculated at birth, not knowing if there is a specific decrease seen from start of chemotherapy. However, the measurement of foetal weight percentiles accurately during pregnancy is difficult, since it is dependent on the

observer, and there are no foetal charts available worldwide which include ethnic and gender differences and the impact of the parental weight and height.

Further research on placental pathophysiology and the effect of specific chemotherapeutic agents, as well as increasing the number of patients in the small subgroups of rare tumour types and treatment modalities, are needed to provide all patients confronted with cancer during pregnancy the best tailor made management plan optimize both obstetrical and neonatal outcome. Participation to the online registry (incipregistration.be) is recommended in order to accomplish this goal.

Research in context

Evidence before this study

We searched PubMed on 03/30/2017 for articles on cohorts of patients with cancer during pregnancy describing obstetrical and oncological outcome published between 01/01/1996 and 12/31/2016, using the following keywords: pregnancy, cancer, tumour, neoplasm, pregnancy outcome and neonatal outcome. The search was restricted to publications in English. A review of references from appropriate articles was done to identify additional studies. This resulted in a large number of articles on cancer before or after pregnancy but not specifically during pregnancy. After selection by abstract and full-text, a total of 71 studies including from n=9 to n=984 patients. A cohort was considered large and was included if it contained 50 or more patients. This has led to a total of 25 articles describing either obstetrical and/or neonatal outcome. No articles on management changes were published. Nine cohorts described the complete group including all sort of malignancies, 5 described breast cancer during pregnancy, 4 haematological cancers, 3 melanoma and 1 cervical cancer, 1 ovarian cancer, 1 thyroid cancer. Overall, 23 studies reported risk or rates of prematurity; 12 found an increased rate or risk of prematurity in cancer in pregnancy and 4 studies did not find an increase. Neonatal outcome was reported to some extent in all studies. One study found an increased rate or risk of neonatal mortality, while 10 did not find such an increase. Increased risk of NICU admission was found in 1 study, while 3 found no such increase. Overall SGA was specified in 22 articles and was increased in 5 articles, while 13 studies did not find an overall increased risk of SGA. None of the studies found an increased rate or risk of congenital anomalies.

Added value of this study

To our knowledge, this is the largest cohort describing both detailed information on clinical management and obstetrical and neonatal outcome. The multiple regression analysis suggested that antenatal chemotherapy may increase the risk of neonatal complications. For SGA, mainly platinum-based chemotherapeutic agents appeared influential. Also, this is the first study evaluating the changes in clinical management and obstetrical and neonatal outcome over years. It appears that during the last 20 years more mothers to be were treated with chemotherapy during pregnancy, resulting in more live births and less prematurity. This observation is indicative of an increased knowledge and awareness about cancer treatment during pregnancy.

Implications of all available evidence

Our study suggests that over the years, oncological treatment during pregnancy increased and prematurity rates decreased. Less prematurity adds to a better neonatal and long-term paediatric outcome. However, the use of chemotherapy during pregnancy may cause neonatal complications like SGA and NICU admission. The long-term paediatric outcome needs to be assessed in more long-term follow-up studies of these children. With the suggested risk factors from our study, it is possible to assess pregnant cancer patients better and refer these obstetrical high risk patient to an academic hospital, where close surveillance in a multidisciplinary setting is provided. Here, paramedical support, psychological guidance and breastfeeding information additionally contribute to an optimal approach.

Acknowledgements

The authors want to thank all medical specialists, outpatient department managers, data and case managers, secretaries and all other persons who collected all data necessary for completing the database. This project is supported by the Research Foundation – Flanders (FWO) in Belgium (grant no. G070514N) and the European Research Council (CRADLE consolidator grant, grant no. ZKD0230) and by Charles University research project Progres Q28-Oncology, UNCE 204013, and by Ministry of Health of the Czech Republic, grant No. 15-28933A. FA is senior clinical investigator and MV are research fellows of the Research Foundation-Flanders (F.W.O.).

Ethical approval

This study was approved by the ethics committee of the University Hospitals Leuven and by every participating centre when needed.

Declaration of interests

Prof. Van Calsteren reports grants from University Hospitals Leuven during the conduct of this study. The other authors declare no conflicts of interest.

Contribution of authorship

FA designed the study. JdH, MV, KVC and FA were involved in the gathering and interpretation of the data and vouch for the data. JdH, MV, KVC, BVC and FA were involved in analysis of the data. All other authors were involved in the gathering of the data. The first draft of the manuscript was written by JdH, MV, KVC, CL and FA, all other authors revised the manuscript for the final draft. All authors agreed with the submitted manuscript.

References

1. Smith LH, Danielsen B, Allen ME, Cress R. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. *Am J Obstet Gynecol* 2003; **189**(4): 1128-35.
2. Lee YY, Roberts CL, Dobbins T, et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study. *BJOG* 2012; **119**(13): 1572-82.
3. Parazzini F, Franchi M, Tavani A, Negri E, Peccatori FA. Frequency of Pregnancy Related Cancer: A Population Based Linkage Study in Lombardy, Italy. *Int J Gynecol Cancer* 2017; **27**(3): 613-9.
4. Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. *J Clin Oncol* 2010; **28**(4): 683-9.
5. Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. *J Clin Oncol* 2009; **27**(1): 45-51.
6. Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. *The Lancet Oncology* 2012; **13**(3): 256-64.
7. Amant F, Vandenbroucke T, Verheecke M, et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. *N Engl J Med* 2015; **373**(19): 1824-34.
8. Lu D, Ludvigsson JF, Smedby KE, et al. Maternal Cancer During Pregnancy and Risks of Stillbirth and Infant Mortality. *J Clin Oncol* 2017; **35**(14): 1522-9.
9. Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study. *The Lancet Oncology* 2012; **13**(9): 887-96.

10. Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. *Am J Clin Oncol* 2010; **33**(3): 221-8.
11. Van Calsteren K, Verbesselt R, Devlieger R, et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. *Int J Gynecol Cancer* 2010; **20**(9): 1456-64.
12. Köhler C, Oppelt P, Favero G, et al. How much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy. *Am J Obstet Gynecol* 2015; **213**(2): 206.e1-5.
13. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med* 2011; **30**(4): 377-99.
14. Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. *Adv Exp Med Biol* 2010; **686**: 349-64.
15. Avilés A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. *Clin Lymphoma* 2001; **2**(3): 173-7.
16. Cardonick E, Gringlas M. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls REPLY. *American Journal of Obstetrics and Gynecology* 2015; **212**(6): 831-2.
17. Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. *Pediatrics* 2004; **114**(2): 372-6.
18. Boucek J, de Haan J, Halaska MJ, et al. Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy. *Laryngoscope* 2017.
19. de Haan J, Lok CA, de Groot CJ, et al. Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma. *Melanoma Res* 2017.
20. Pallotto EK, Kilbride HW. Perinatal outcome and later implications of intrauterine growth restriction. *Clin Obstet Gynecol* 2006; **49**(2): 257-69.
21. Sankaran S, Kyle PM. Aetiology and pathogenesis of IUGR. *Best Pract Res Clin Obstet Gynaecol* 2009; **23**(6): 765-77.
22. Salafia CM. Placental pathology of fetal growth restriction. *Clin Obstet Gynecol* 1997; **40**(4): 740-9.

23. Wadhwa PD, Garite TJ, Porto M, et al. Placental corticotropin-releasing hormone (CRH), spontaneous preterm birth, and fetal growth restriction: a prospective investigation. *Am J Obstet Gynecol* 2004; **191**(4): 1063-9.
24. Nulman I, Laslo D, Fried S, Uleryk E, Lishner M, Koren G. Neurodevelopment of children exposed in utero to treatment of maternal malignancy. *Br J Cancer* 2001; **85**(11): 1611-8.

Table 1. Patient characteristics.

Characteristic	Result
All patients, n=1170	
Age at diagnosis in years	
Median (IQR)	32 (29-36)
Range	16-53
Missing, n	13
Period of diagnosis	
1996 – 2004	257 (22)
2005 – 2009	376 (32)
2010 – 2016	537 (46)
Trimester of diagnosis, n (%)^a	
Pregnant during treatment	76 (7)
First trimester	266 (24)
Second trimester	490 (45)
Third trimester	266 (24)
Missing	72
Parity at diagnosis, n (%)	
Nulliparous	486 (44)
Multiparous	625 (56)
Missing	59
Stage of disease	
Local or regional	893 (79)
Systemic ^b	232 (21)
Missing	45
Treatment received during pregnancy, n (%)^c	
No treatment during pregnancy	391 (33)
Surgery	454 (39)
- Abdominal/cervical surgery	149 (33)
Chemotherapy ^d	429 (37)
- Anthracyclines	328 (78)
- Alkylating (excl. platinum)	292 (69)
- Antimetabolite	108 (26)
- Taxanes	84 (20)
- Platinum	74 (18)
- Other	97 (23)
- Missing	6
Radiotherapy	29 (3)
Targeted therapy	33 (3)
Other therapy	52 (4)
All singleton live & still births, n=969	
Adverse obstetrical outcome	
PPROM and/or preterm contractions	98 (10)
All singleton live births, n=955	
Adverse neonatal outcome	
Small-for-gestational-age	167/796 (21)
Neonatal intensive care unit admission	298/720 (41)

PPROM, preterm prelabour rupture of membranes

^a Stratification per malignancy group can be found in the Appendix, page 11.

^b Systemic disease was defined as TNM or FIGO stage IV disease and leukaemia, non-systemic disease was defined as TNM or FIGO stage I to III and all brain cancers.

^c Patients with multiple treatment modalities during pregnancy are placed in all applicable groups, hence percentages add up to more than 100. Stratification per malignancy group of the different treatment combinations given during pregnancy is shown in Appendix, page 12.

^d Combination regimens consisting of more than one chemotherapeutic agent were registered in 83% of the patients.

Table 2. Overview of different treatment modalities per malignancy for all 1170 patients. Patients with multiple treatment modalities during pregnancy are placed in all applicable groups.

	Total	No treatment	Surgery	Chemotherapy	Radiotherapy	Targeted and hormonal therapy ^a	Other therapy ^b
	n	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Breast	462	116 (25)	225 (49)	248 (54)	12 (3)	7 (2)	-
Cervix	147	83 (56)	32 (22)	37 (25)	2 (1)	-	-
Lymphoma	113	41 (36)	8 (7)	66 (58)	4 (4)	18 (16)	-
Ovarian	88	23 (26)	64 (73)	21 (24)	-	-	-
Leukaemia	68	22 (32)	-	23 (34)	1 (1)	7 (10)	15 (22)
Gastro-intestinal	49	19 (39)	21 (43)	16 (33)	-	-	-
Melanoma	46	12 (26)	33 (72)	-	2 (4)	-	-
Thyroid	37	7 (19)	30 (81)	-	1 (3)	-	-
Brain	21	11 (52)	10 (48)	1 (5)	1 (5)	-	-
Other	139	57 (41)	31 (22)	17 (12)	6 (4)	1 (1)	37 (27)
Total	1170	391 (33)	454 (39)	429 (37)	29 (2)	33 (3)	52 (4)

^a Targeted and hormonal therapy include rituximab n=18, imatinib n=7, trastuzumab n=3, tamoxifen n=3, lorlatinib n=1 and trastuzumab + pertuzumab n=1.

^b Other therapies include interferon n=52.

Table 3. Obstetrical outcome, stratified by malignancy for all singleton pregnancies with known obstetrical outcome, n=1089/1107, 98%).

	Total	Miscarriage	TOP	Still birth ^a	Live birth < 37 weeks	Live birth ≥ 37 weeks	Live birth GA Unknown	Maternal death during pregnancy
Malignancy	n	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Breast cancer	428	6 (1)	26 (6)	1 (<1)	184 (43)	182 (43)	28 (7)	1 (<1)
Cervical cancer	140	2 (1)	21 (15)	2 (1)	72 (51)	37 (26)	6 (4)	-
Lymphoma	107	-	8 (8)	3 (3)	48 (45)	45 (42)	3 (3)	-
Ovarian cancer	83	3 (4)	3 (4)	-	21 (25)	53 (64)	3 (4)	-
Leukaemia	64	5 (8)	6 (9)	2 (3)	26 (41)	25 (39)	-	-
Gastro-intestinal cancer	47	2 (4)	4 (9)	2 (4)	29 (62)	8 (17)	1 (2)	1 (2)
Melanoma	43	-	2 (5)	-	3 (7)	34 (79)	3 (7)	1 (2)
Thyroid cancer	37	-	4 (11)	-	1 (3)	32 (87)	-	-
Brain cancer	19	-	2 (11)	-	9 (47)	6 (32)	-	2 (11)
Other malignancies	121	2 (2)	19 (16)	4 (3)	37 (31)	36 (30)	23 (19)	-
Total	1089	20 (2)	95 (9)	14 (1)	430 (40)	458 (42)	67 (6)	5 (1)

TOP, termination of pregnancy; GA, gestational age;

^a Still births consisted of 7 intra-uterine deaths, 7 perinatal deaths.

Table 4. Multivariable analysis of the most common obstetrical and neonatal complications. For preterm prelabour rupture of membranes (PPROM)/preterm contractions, we analysed singleton stillbirths and live births (n=969), for the neonatal complications we analysed singleton live births (n=955). We handled missing data using multiple imputation.

Covariate	PPROM/preterm contractions		Small-for-gestational-age		Neonatal intensive care unit admission	
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Malignancy						
Breast cancer	Reference ^a	0.16	Reference ^a	0.86	Reference ^a	<0.0001
Cervical cancer	0.74 (0.27-2.04)		0.75 (0.36-1.55)		2.22 (1.19-4.15)	
Lymphoma	1.24 (0.49-3.12)		1.17 (0.52-2.60)		1.04 (0.53-2.04)	
Ovarian cancer	0.60 (0.16-2.30)		0.39 (0.14-1.09)		0.60 (0.26-1.38)	
Leukaemia	2.45 (0.80-7.48)		0.68 (0.23-2.03)		1.27 (0.53-3.03)	
Gastro-intestinal cancer	0.33 (0.06-1.96)		0.80 (0.29-2.22)		7.13 (2.86-17.7)	
Melanoma	0.76 (0.19-3.12)		0.90 (0.29-2.76)		0.36 (0.13-1.04)	
Thyroid cancer	0.52 (0.09-3.12)		0.73 (0.21-2.58)		0.14 (0.02-0.90)	
Other malignancies	0.44 (0.15-1.31)		0.82 (0.36-1.83)		1.42 (0.73-2.75)	
Period of diagnosis						
1996-2004	Reference ^b	0.69	Reference ^b	0.32	Reference ^b	0.019
2005-2009	0.81 (0.44-1.48)		0.77 (0.45-1.31)		0.73 (0.48-1.11)	
2010-2016	0.77 (0.43-1.39)		1.04 (0.63-1.73)		0.55 (0.36-0.84)	
Age at diagnosis (per 5 years)	1.08 (0.86-1.35)	0.53	1.36 (1.11-1.68)	0.0033	0.98 (0.82-1.17)	0.65
Diagnosis in 3 rd trimester vs. before	0.64 (0.35-1.15)	0.14	0.78 (0.48-1.27)	0.33	1.13 (0.77-1.65)	0.52
Systemic vs. non-systemic disease	1.43 (0.70-2.92)	0.34	1.86 (1.04-3.33)	0.039	1.14 (0.68-1.93)	0.52
Chemotherapeutic agents						
Alkylating (yes vs. no)	2.02 (0.81-5.02)	0.056	2.08 (0.88-4.91)	<0.0001	0.88 (0.46-1.70)	0.0086 ^c
Anthracyclines (yes vs. no)	1.11 (0.42-2.92)		0.50 (0.21-1.22)		1.21 (0.62-2.38)	
Antimetabolite (yes vs. no)	0.89 (0.46-1.71)		1.24 (0.70-2.22)		1.03 (0.60-1.74)	
Taxanes (yes vs. no)	1.11 (0.53-2.33)		2.07 (1.11-3.86)		2.37 (1.31-4.28)	
Platinum (yes vs. no)	2.29 (0.79-6.63)		3.12 (1.45-6.70)		1.66 (0.77-3.55)	
Other (yes vs. no)	1.48 (0.61-3.63)		2.34 (1.04-5.25)		1.63 (0.78-3.38)	
Abdominal/cervical surgery (yes vs. no)	0.42 (0.15-1.16)	0.083	1.31 (0.67-2.59)	0.45	0.30 (0.17-0.55)	<0.0001

^a We used the largest group as reference category (breast cancer).

^b We used the first time period as reference category (1996-2004).

P-values are related to the null hypothesis that all odds ratios to which they refer are 1. For malignancy, these are the odds ratios of all malignancy types vs. breast cancer. For period of diagnosis, these are the odds ratios of each period vs. the first. For chemotherapeutic agents, the p-value refers to the simultaneous association of the administration all six agents with the outcome. All other p-values refer to only one odds ratio.

Figure 1. Flow chart with inclusion process.






Figure 2. Distribution of malignancies during pregnancy (A) and stage of disease (B) at diagnosis per malignancy. Stage of disease was available for all solid malignancies with TNM or FIGO classification.



* Ovarian cancers include borderline ovarian tumours.

**The group with other malignancies consists of 25 different malignancy types.

Figure 3. Changes in management (A) and obstetrical outcome (B) over 20 years. Management changes are shown for all 1170 patients, obstetrical outcome is shown for all singleton pregnancies.



Supplementary appendix

This appendix is part of the original submission and has been provided by the authors to give readers additional information about their work.

Oncological management and pregnancy outcomes in women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients.

Jorine de Haan, Magali Verheecke, Kristel Van Calsteren, Ben Van Calster, Roman G. Shmakov, Mina Mhallem Gziri, Michael J. Halaska, R. Fruscio, Christianne A.R. Lok, Ingrid A. Boere, Paolo Zola, Petronella B. Ottevanger, Christianne J.M. de Groot, Fedro A. Peccatori, Karina Dahl Steffensen, Elyce H. Cardonick, Evgeniya Polushkina, Lukas Rob, Lorenzo Ceppi, Gennady T. Sukhikh, Sileny N. Han, Frédéric Amant. *On behalf of the International Network on Cancer, Infertility and Pregnancy (INCIP).*

Table of contents

1. General information.....	28
1.1. Hypotheses prior to start study.....	28
1.2. Description of the protocol.	Fout! Bladwijzer niet gedefinieerd.
1.3 Parameters of the percentile calculator.....	29
1.4 Additional information on multiple imputation of missing values.	30
1.5 Obtaining relative risks to express changes over time.	31
1.6 Participating centres.	32
1.7 Recruitment per centre	33
2 Results.....	34
2.1 Missing values.....	34
2.2 Oncologic data, descriptives.	36
2.3 Obstetrical outcome data, descriptives.....	38
2.4 Neonatal outcome data, descriptives.....	41
2.5 Multiple logistic regression analysis.	45
2.6 Changes in 20 years of treatment in pregnant cancer patients.	50
2.7 Cohorts of cancer during pregnancy in the literature.	51
3 Participating investigators.....	56
4 References.....	57

1. General information.

1.1. Hypotheses prior to start study.

We hypothesized that cancer and cancer treatment during pregnancy results in a higher number of obstetrical complications and may impact the neonatal outcome. We were particularly interested in the following outcome measures; preterm prelabour rupture of membranes (PPROM) and/or preterm contractions, small-for-gestational-age (SGA) and neonatal intensive care unit admission (NICU). Moreover, we were interested in changes in therapy exposure and obstetrical and neonatal outcome over time.

PPROM and/or preterm contractions:

- Antenatal chemotherapy exposure will increase the risk of PPRM and/or preterm contractions.
- Systemic disease will increase the risk of PPRM and/or preterm contractions.
- Cervical or abdominal surgery during pregnancy will increase the risk of PPRM and/or preterm contractions.

SGA:

- Antenatal chemotherapy exposure will increase the risk of SGA.
- Chemotherapy agents with high placenta crossing will have a stronger effect on SGA (e.g. alkylating agents)
- Starting chemotherapy before the end of placental development may have stronger effect on SGA (before 16 weeks GA)
- Systemic disease will increase the risk of SGA.
- Diagnosis in the 3rd trimester will decrease the risk of SGA.

NICU admission:

- Antenatal chemotherapy exposure will increase the risk of NICU admission.
- Diagnosis in the 3rd trimester will decrease the risk of NICU admission.
- Diagnosis in an earlier period of time will increase the risk of NICU admission.

Changes over time:

- Type of malignancy will not change over time
- Stage of disease will decrease over time
- Chemotherapy exposure will increase over time
- Premature delivery will decrease over time
- SGA will increase over time due to increased antenatal chemotherapy exposure.

1.2. Parameters of the percentile calculator.

Table A1. Available data of the included parameters to calculate the birth weight percentiles in 796 cases of 955 singleton live births with available GA at birth and birth weight.

Parameters	Study group (n=796)			
	Chemotherapy-exposed (n=353)		Non-exposed (n=443)	
	Median (IQR)/ n (%)	Available n (%)	Median (IQR)/ n (%)	Available n (%)
GA at delivery (days)	256 (242-266)		261 (245-275)	
Birth weight (g)	2632 (2186-3025)		2950 (2430-3340)	
Gender offspring		341 (97%)		416 (94%)
Male	179 (52%)		204 (49%)	
Female	162 (48%)		212 (51%)	
Ethnicity mother		259 (73%)		283 (64%)
Caucasian	192 (74%)		208 (73%)	
African	17 (7%)		12 (4%)	
Asian (incl. Russian)	42 (16%)		56 (20%)	
Other	8 (3%)		7 (2%)	
Maternal length (cm)	166 (162-170)	281 (80%)	167 (163-172)	288 (65%)
Maternal weight at booking (kg)	66 (59-77)	267 (76%)	65 (59-74)	283 (64%)
Parity		342 (97%)		428 (97%)
Primiparae	151 (44%)		214 (50%)	
Multiparae	191 (56%)		214 (50%)	

In case of missing values for the different parameters the software uses the average between male and female coefficients (gender), other European origin (ethnicity), 165cm (maternal length) and 68kg (maternal weight).

1.3. Additional information on multiple imputation of missing values.

For the multiple regression analyses, missing values for covariates and outcomes were addressed using multiple imputation based on the method of chained equations.¹ We used the mice package in R to carry out the imputations.² Imputations were based on all the variables included in the procedure, which are the covariates of the logistic regression models, as well as other auxiliary variables that are likely predictive of missingness or of the value of incomplete variables. The procedure assumes that data are ‘missing at random’ (MAR), which means that missing values have occurred randomly conditional on the variables in the imputation procedure.

We used the following variables in the imputation process: age at diagnosis (years), malignancy type (breast, cervix, lymphoma, ovarian, leukaemia, gastro-intestinal, melanoma, thyroid, brain, other haematological malignancies, other), systemic disease, abdominal/cervical surgery, period of diagnosis (<2005, 2005-2009, 2010-2016), diagnosis in the third trimester (yes/no), preterm status (not preterm, spontaneous preterm, iatrogenic preterm), birth weight, SGA, NICU admission, PPROM, and six binary variables about the administration of different chemotherapeutic agents (anthracyclines, alkylating chemotherapy (non-platinum), antimetabolite chemotherapy, platinum, taxanes, and any other chemotherapeutic agents).

Missing values were imputed 25 times. The regression models are fitted on each of the 25 completed datasets, and results were combined using standard Rubin’s rules. Based on recent research, we decided to impute missing outcomes and include patients with missing outcome in the analysis.³ As a sensitivity analysis, we compared results based on imputed data with results based on complete case analysis.⁴

1.4 Obtaining relative risks to express changes over time.

To investigate changes over time, we use univariable log-binomial regression models with year of diagnosis as continuous predictor. The coefficient b for year of diagnosis is transformed into a relative risk as a summary of the average evolution every five calendar years by calculating $\exp(b/5)$.


1.5 Participating centres.

Table A2. Overview of participating centres.

Country	City	Centre
Austria	Graz	University Hospital of Obstetrics and Gynaecology
Belgium	Antwerp	Antwerp University Hospital
Belgium	Brussels	Cliniques Universitaires St-Luc U.C.L.
Belgium	Leuven	University Hospital Leuven
Chile	Talcahuano	Hospital Las Higueras de Talcahuano
Czech Republic	Prague	3rd Medical Faculty Charles University
Denmark	Vejle	Vejle Hospital
France	Paris	Bichat – Claude-Bernard Hospital
Germany	Freiburg	University Hospital of Freiburg
Great Britain	Derby	Royal Derby Hospital
Greece	Athens	Alexandra General Hospital
Greece	Ioannina	Ioannina University Hospital
Greece	Thessaloniki	Papageorgiou Hospital
Italy	Milan	European Institute of Oncology
Italy	Milan 2	San Raffaele Hospital Milan
Italy	Milan 3	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano
Italy	Monza	San Gerardo Hospital
Italy	Turin	University of Turin
Italy	Turin 2	Mauriziano
Poland	Gdansk	Regional Oncology Center
Poland	Krakow	Macierzynstwo Medical Center
Poland	Krakow 2	University Hospital of Krakow
Poland	Warsaw	Maria Sklodowska-Curie Memorial Cancer Center
Russia	Moscow	Research Center for Obstetrics
Russia	Moscow 2	N.N. Blochin Cancer Research Center
Spain	Madrid	La Paz University Hospital
Spain	Madrid 2	MD Anderson Cancer Center
Switzerland	Lausanne	University Hospital of Lausanne
the Netherlands	Amsterdam	Antoni van Leeuwenhoek - Netherlands Cancer Institute
the Netherlands	Amsterdam 2	VU University Medical Center
the Netherlands	Amsterdam 3	Academical Medical Center Amsterdam
the Netherlands	Groningen	University Medical Center Groningen
the Netherlands	Nijmegen	Radboud University Nijmegen Medical Center
the Netherlands	Rotterdam	Erasmus Medical Center Rotterdam
the Netherlands	Utrecht	University Medical Center Utrecht
the Netherlands	-	Other non-academic hospitals in the Netherlands
United States of America	Camden	Cooper University Hospital

1.6 Recruitment per centre

Figure A1. Plot of inclusion and distribution of registered cases per centre. For Cooper University Hospital (Camden, New Jersey, USA), we only received period of diagnosis (<2005, 2005-2009, 2010-2016). For this reason we could not show specific dates of diagnosis for this centre.



2 Results

2.1 Missing values.

Table A3. Overview of missing data by period of diagnosis.

Variable	Missing values by period of diagnosis, n (%)			
	<2005	2005-2009	2010-2016	Overall
All patients, n	257	376	537	1170
Age at diagnosis	4 (2)	3 (1)	6 (1)	13 (1)
Year of diagnosis	15 (6)	8 (2)	11 (2)	34 (3)
Trimester at diagnosis	21 (8)	27 (7)	24 (4)	72 (6)
Malignancy type	0	0	0	0
Systemic disease	8 (3)	14 (4)	23 (4)	45 (4)
No treatment	0	0	0	0
Surgery	0	0	0	0
Abdominal/cervical surgery	0	0	0	0
Chemotherapy	0	0	0	0
Radiotherapy	0	0	0	0
Targeted therapy	0	0	0	0
Other therapy	0	0	0	0
Autoimmune disorders	0	0	0	0
Obstetrical outcome	2 (1)	8 (2)	18 (3)	28 (2)
Selected malignancies, n^a	225	329	482	1036
Disease stage	8 (4)	16 (5)	23 (5)	47 (5)
All patients with chemotherapy, n^a	63	132	234	429
Chemotherapeutic agent(s)	0	2 (2)	4 (2)	6 (1)
Live births and still births, n	213	320	465	998
Singleton vs. multiple	0	0	0	0
Singleton live and still births, n	206	310	453	969
Each of the obstetrical complications ^b	0	0	0	0
Singleton live births, n	199	306	450	955
Preterm delivery <37 weeks	19 (10)	23 (8)	26 (6)	68 (7)
Spontaneous preterm delivery	19 (10)	26 (8)	26 (6)	71 (7)
Small-for-gestational-age (SGA)	38 (19)	53 (17)	68 (15)	159 (17)
NICU admission	52 (26)	80 (26)	103 (23)	235 (25)
Congenital malformations	70 (35)	78 (25)	86 (19)	234 (25)
Apgar<7 at 5 minutes	66 (33)	74 (24)	92 (20)	232 (24)

NICU, neonatal intensive care unit.

^a Excluding leukaemia, other haematological, and brain cancer

^b Cholestasis, chorio-amnionitis, gestational diabetes, hypertensive disorders, maternal infection, preterm prelabour rupture of membranes/preterm contractions, vaginal bleeding, stillbirth, and other complications including hypothyroidism, thromboembolic events, skin conditions, poly- and oligohydramnios. There will probably have been some missing values, because these complications were only registered when observed, whereas absence of a complication was not explicitly registered as such.

Table A4. Overview of missing data for neonatal outcomes by centre for singleton live births (n=955).

Center	N	Small-for-gestational-age (SGA) missing, n	Neonatal intensive care unit (NICU) admission missing, n	Missing values, %
University of Turin	37	0	0	0
AMC Amsterdam	16	0	0	0
University Medical Center Groningen	3	0	0	0
Antwerp UH	3	0	0	0
Alexandra GH (Athens)	2	0	0	0
Blochin CRC Moscow	2	0	0	0
Regional Oncology Center (Gdansk)	1	0	0	0
La Paz UH (Madrid)	10	1	0	5
Cliniques Universitaires St-Luc U.C.L. (Brussels)	88	5	7	7
Non academic hospitals (Netherlands)	14	1	1	7
UH Leuven	164	10	17	8
University Medical Center Utrecht	16	3	0	9
San Raffaele Hospital Milan	5	1	0	10
Erasmus Medical Center (Rotterdam)	42	5	6	13
Cooper UH	26	0	9	17
UH Freiburg	10	1	3	20
San Gerardo Hospital (Monza)	75	18	13	21
Radboud University Nijmegen	39	7	9	21
VU Medical Center (Amsterdam)	29	5	7	21
Vejle Hospital	26	7	4	21
Charles University (Prague)	76	8	25	22
Papageorgiou (Thessaloniki)	3	1	1	33
UH Graz	10	3	4	35
European Institute of Oncology (Milan)	35	17	9	37
Research Center for Obstetrics (Moscow)	108	21	62	38
UH Lausanne	8	2	4	38
AVL Netherlands Cancer Institute (Amsterdam)	69	32	23	40
Royal Derby Hospital	5	1	3	40
Maria Skłodowska-Curie MCC (Warsaw)	10	4	6	50
MD Anderson (Madrid)	1	0	1	50
UH Krakow	1	0	1	50
Macierzynstwo MC (Krakow)	10	1	10	55
Ioannina UH	8	2	8	63
Mauriziano (Turin)	2	2	1	75
Hospital Las Higueras de Talcahuano	1	1	1	100
Hopital BCB (Paris)	0	-	-	-
Ospedale Maggiore (Milan)	0	-	-	-
<i>All centers</i>	<i>955</i>	<i>159</i>	<i>235</i>	<i>21</i>

2.2 Oncologic data, descriptives.

Table A5. Trimester at diagnosis per malignancy for all patients (n=1170).

Malignancy	Total	Trimester at diagnosis, n (%)				Unknown
		Before pregnancy	First trimester	Second trimester	Third trimester	
Breast cancer	462	23 (5)	112 (26)	180 (42)	117 (27)	30
Cervical cancer	147	3 (2)	35 (25)	64 (45)	40 (28)	5
Lymphoma	113	3 (3)	14 (13)	70 (64)	23 (21)	3
Ovarian cancer	88	0	33 (39)	39 (46)	12 (14)	4
Leukaemia	68	18 (27)	14 (21)	18 (27)	17 (25)	1
Gastro-intestinal cancer	49	2 (4)	11 (23)	23 (48)	12 (25)	1
Melanoma	46	2 (4)	13 (28)	18 (39)	13 (28)	0
Thyroid cancer	37	3 (8)	14 (38)	18 (49)	2 (5)	0
Brain cancer	21	1 (5)	2 (10)	9 (43)	9 (43)	0
Other malignancies	139	21 (19)	18 (16)	51 (46)	21 (19)	28
All	1170	76 (7)	266 (24)	490 (45)	266 (24)	72

Table A6. Treatment combination by malignancy for all patients. (n=1170).

Malignancy	Treatment combination, n (%)													
	n	NT	S	CT	S CT	OT	TT	CT TT	S CT RT	S RT	RT	CT RT	CT RT TT	S CT TT
Breast	462	116 (25)	89 (19)	112 (24)	127 (27)	-	5 (1)	1 (<1)	7 (2)	2 (<1)	2 (<1)	-	1 (<1)	-
Cervix	147	83 (56)	27 (18)	31 (21)	4 (3)	-	-	-	1 (1)	-	-	1 (1)	-	-
Lymphoma	113	41 (36)	3 (3)	45 (40)	2 (2)	-	-	17 (15)	-	2 (2)	1 (1)	1 (1)	-	1 (1)
Ovarian	88	23 (26)	44 (50)	1 (11)	20 (23)	-	-	-	-	-	-	-	-	-
Leukaemia	68	22 (32)	-	23 (34)	-	15 (22)	7 (10)	-	-	-	1 (1)	-	-	-
Gastro-intestinal	49	19 (39)	14 (29)	9 (18)	7 (14)	-	-	-	-	-	-	-	-	-
Melanoma	46	12 (26)	32 (70)	-	-	-	-	-	-	1 (2)	1 (2)	-	-	-
Thyroid	37	7 (19)	29 (78)	-	-	-	-	-	-	1 (3)	-	-	-	-
Brain	21	11 (52)	9 (43)	-	-	-	-	-	1 (5)	-	-	-	-	-
Other	139	57 (41)	25 (18)	11 (8)	2 (1)	36 (26)	1 (1)	-	2 (1)	2 (1)	1 (1)	1 (1)	-	-
All	1170	391 (33)	272 (23)	233 (20)	162 (14)	51 (4)	13 (1)	18 (2)	11 (1)	8 (1)	6 (1)	3 (<1)	1 (<1)	1 (<1)

NT, no treatment; S, surgery; CT, chemotherapy; RT, radiotherapy; TT, targeted therapy; OT, other treatment.

2.3 Obstetrical outcome data, descriptives.

Table A7. Termination of pregnancy per malignancy type per period of diagnosis. n(%).

	1996-2004	2005-2009	2010-2016
Breast cancer	13/90 (14)	13/150 (9)	10/212 (5)
Cervical cancer	5/38 (13)	9/43 (21)	9/64 (14)
Lymphoma	2/24 (8)	2/38 (5)	4/48 (8)
Ovarian cancer	1/28 (3)	-	2/29 (7)
Leukaemia	3/15 (20)	1/19 (5)	2/32 (6)
Gastro-intestinal cancer	1/13 (8)	2/9 (22)	2/27 (7)
Melanoma	-	1/13 (7)	1/17 (5)
Thyroid cancer	-	4/15 (27)	-
Brain cancer	1/4 (25)	-	1/12 (8)
All other	6/29 (21)	6/48 (12)	12/57 (20)

Table A8. Oncological and obstetrical specification for patients with singleton pregnancy whose pregnancy ended immature, with death of mother or because of intra-uterine fetal death.

Pregnancy ending	Malignancy type	Treatment during pregnancy	Period of diagnosis	Trimester at diagnosis	Trimester of pregnancy ending	Trimester at first surgery	Location of surgery	Trimester at start CT	Trimester at start RT
Immature	Ewing's sarcoma	Chemotherapy	2010 - 2016	First	Second			Second	
Immature	Acute Myeloid Leukaemia	Chemotherapy	2010 - 2016	Second	Second			Second	
Immature	Breast cancer	Surgery	2005 - 2009	First	Second	Second	Breast		
Immature	Hodgkin lymphoma	No treatment	< 2005	First	Second				
Immature	Hodgkin lymphoma	No treatment	< 2005	First	Second				
Immature	Gastric cancer	Surgery	< 2005	Second	Second	Second	Intra-abdominal		
Immature	Oesophageal cancer	Surgery	2005 - 2009	Second	Second	Second	Trans-oesophageal		
Maternal death	Breast cancer	Surgery	2010 - 2016	First	Third	Third	Breast		
Maternal death	Melanoma	Surgery	< 2005	Second	Third	Third	Skin		
Maternal death	Brain tumour	Surgery	2010 - 2016	Second	Third	Third	Intracerebral		
Maternal death	Brain tumour	Surgery	2005 - 2009	Second	Second	Second	Intracerebral		
Maternal death	Gastric cancer	Surgery	2005 - 2009	Second	Second	Second	Intra-abdominal		
IUFD	Cervical cancer	Chemotherapy and radiotherapy	< 2005	Second	Second			Second	Second
IUFD	Hodgkin lymphoma	Surgery and chemotherapy	< 2005	Second	Third	Second	Lymph node excision	Second	
IUFD	Essential thrombocythemia	Chemotherapy	< 2005	Before pregnancy	Third				
IUFD	Cervical cancer	No treatment	2005 - 2009	Second	Third				
IUFD	Acute Myeloid Leukaemia	No treatment	2005 - 2009	Second	Second				
IUFD	Primary myelofibrosis	Immune therapy	< 2005	Unknown	Third				
IUFD	Kidney cancer	Surgery	2010 - 2016	Second	Third	Second	Retroperitoneal		

IUFD, intra-uterine fetal death; CT, chemotherapy; RT, radiotherapy.

Table A9. Obstetric complications per malignancy (singleton live & still births, n=969).

Malignancy	n	Any n (%)	PPROM/ preterm contractions n (%)	Maternal infection n (%)	Hypertensive disorders n (%)	Gestational diabetes n (%)	Vaginal Bleeding n (%)	Still- birth n (%)	Chole- stasis n (%)	Chorio- amnionitis n (%)	Other ^a n (%)
Breast cancer	395	81 (21)	46 (12)	10 (3)	7 (2)	7 (2)	3 (1)	1 (<1)	2 (1)		11 (3)
Cervical cancer	117	27 (23)	8 (7)	3 (3)	3 (3)	3 (3)	7 (6)	2 (2)	1 (1)		8 (7)
Lymphoma	99	34 (34)	19 (19)	7 (7)	3 (3)	1 (1)	1 (1)	3 (3)			4 (4)
Ovarian	77	10 (13)	3 (4)	1 (1)	2 (3)	3 (4)			1 (1)		1 (1)
Leukaemia	53	25 (47)	13 (25)	5 (9)	3 (6)	6 (11)	1 (2)	2 (4)	1 (2)		6 (11)
Gastro- intestinal	40	11 (28)	1 (3)	1 (3)	5 (13)	1 (3)		2 (5)			2 (5)
Melanoma	40	6 (15)	2 (5)	1 (3)		1 (3)	1 (3)		1 (3)		3 (8)
Thyroid	33	5 (15)	1 (3)	1 (3)	1 (3)	2 (6)			1 (3)		
Brain	15	4 (27)				2 (13)					3 (20)
Other malignancies	100	22 (22)	5 (5)	3 (3)	5 (5)	1 (1)	1 (1)	4 (4)	1 (1)	1 (1)	5 (5)
All	969	225 (23)	98 (10)	32 (3)	29 (3)	27 (3)	14 (1)	14 (1)	8 (1)	1 (<1)	43 (4)

PPROM, preterm prelabour rupture of membranes.

^a Other complications are all reported obstetrical and medical complications, including hypothyroidism, thromboembolic events, skin conditions, poly- and oligohydramnios.

2.4 Neonatal outcome data, descriptives.

Table A10. Overview of reported outcomes on the neonatal outcomes (singleton live births, n=955).

Neonatal complication	n (%)
Preterm delivery	429/887 (48%)
Spontaneous preterm delivery	53/884 (6%)
Small-for-gestational-age	167/796 (21%)
Congenital malformations	32/721 (4%)
NICU admission	298/720 (41%)
Apgar score <7 at 5 minutes	18/723 (2%)

NICU, neonatal intensive care unit.

Table A11. Neonatal outcomes stratified by different variables (singleton live births, n=955).

	Presence of neonatal complication, n/N (%)			
	Premature delivery	SGA	NICU	Congenital Malformations
Period of diagnosis				
<2005 (n=199)	97/180 (54)	33/161 (20)	73/147 (50)	12/129 (9)
2005-2009 (n=306)	146/283 (52)	43/253 (17)	93/226 (41)	9/228 (4)
2010-2016 (n=450)	186/424 (44)	91/382 (24)	132/347 (38)	11/364 (3)
Age				
<25 (n=57)	29/49 (59)	4/46 (9)	21/39 (54)	2/50 (4)
25-35 (n=631)	268/587 (46)	106/528 (20)	198/475 (42)	16/467 (3)
>35 (n=258)	127/244 (52)	55/214 (26)	79/204 (39)	14/202 (7)
BMI				
<20 (n=80)	40/79 (51)	18/72 (25)	29/64 (45)	2/64 (3)
20-25 (n=310)	130/285 (46)	46/261 (18)	94/233 (40)	8/255 (3)
>25 (n=220)	103/209 (49)	49/197 (25)	68/179 (38)	11/181 (6)
Missing (n=345)	156/314 (50)	54/266 (20)	107/244 (44)	11/221 (5)
Smoking				
No (n=578)	263/546 (48)	99/505 (20)	181/446 (41)	16/468 (3)
Yes (n=118)	56/108 (52)	34/95 (36)	42/98 (43)	5/93 (5)
Missing (n=259)	110/233 (47)	34/196 (17)	75/176 (43)	11/160 (7)
Substance abuse				
No (n=630)	287/599 (48)	117/550 (21)	197/497 (40)	19/517 (4)
Yes (n=28)	15/26 (58)	9/24 (38)	15/25 (60)	1/19 (5)
Missing (n=297)	127/262 (48)	41/222 (18)	86/198 (43)	12/185 (6)
Tumour type				
Breast cancer (n=394)	184/366 (50)	70/329 (21)	118/317 (37)	17/293 (6)
Cervical cancer (n=115)	72/109 (66)	21/95 (22)	45/84 (53)	1/80 (1)
Lymphoma (n=96)	48/93 (52)	25/89 (28)	33/71 (46)	4/84 (5)
Ovarian cancer (n=77)	21/74 (28)	10/63 (16)	12/56 (21)	3/60 (5)
Leukaemia (n=51)	25/50 (50)	9/47 (19)	21/45 (47)	3/44 (7)
Gastro-intestinal cancer (n=38)	29/37 (78)	10/34 (29)	26/36 (72)	1/34 (3)
Melanoma (n=40)	3/37 (8)	4/27 (15)	4/28 (14)	0/25 (0)
Thyroid cancer (n=33)	1/33 (3)	3/29 (10)	1/19 (5)	0/19 (0)
Brain cancer (n=15)	9/15 (60)	1/13 (8)	8/11 (73)	0/12 (0)
Other malignancies (n=96)	37/73 (51)	14/70 (20)	30/53 (57)	3/70 (4)
Disease stage				
Systemic (n=175)	331/709 (47)	125/630 (20)	221/576 (38)	26/566 (5)
Local (n=747)	86/149 (58)	37/142 (26)	72/124 (58)	5/135 (4)
Missing (n=33)	12/29 (41)	5/24 (21)	5/20 (25)	1/20 (5)
Treatment during pregnancy				
No (n=264)	137/251 (55)	30/216 (14)	97/192 (51)	9/181 (5)
Yes (n=691)	292/636 (46)	137/580 (24)	201/528 (38)	23/540 (4)
Chemotherapy				
No (n=563)	217/507 (43)	68/443 (15)	152/397 (38)	14/393 (4)
Yes (n=392)	212/380 (56)	99/353 (28)	146/323 (45)	18/328 (5)
Surgery				
No (n=556)	288/513 (56)	93/463 (20)	197/404 (49)	17/417 (4)
Yes (n=399)	141/374 (38)	74/333 (22)	101/316 (32)	15/304 (5)
Abdominal/cervical surgery reported				
No (n=822)	387/767 (50)	146/691 (21)	277/619 (45)	25/610 (4)
Yes (n=133)	42/120 (35)	21/105 (20)	21/101 (21)	7/111 (6)
Radiotherapy				
No (n=933)	420/867 (48)	160/778 (21)	291/702 (41)	30/703 (4)
Yes (n=22)	9/20 (45)	7/18 (39)	7/18 (39)	2/18 (11)
Targeted therapy				
No (n=922)	417/859 (49)	155/769 (20)	287/696 (41)	31/696 (4)
Yes (n=33)	12/28 (43)	12/27 (44)	11/24 (46)	1/25 (4)
Autoimmune disorders reported				
No	415/868 (48)	163/780 (21)	290/704 (41)	31/706 (4)
Yes	14/19 (74)	4/16 (25)	8/16 (50)	1/15 (7)
Trimester at diagnosis				
Before pregnancy (n=52)	14/47 (30)	11/45 (24)	13/34 (38)	2/42 (5)
First (n=175)	68/169 (40)	34/152 (22)	43/135 (32)	5/137 (4)
Second (n=422)	216/415 (52)	89/369 (24)	144/333 (43)	16/337 (5)
Third (n=256)	128/253 (51)	33/216 (15)	92/201 (46)	8/178 (4)
Missing (n=50)	3/3 (100)	0/14 (0)	6/17 (35)	1/27 (4)
Labour				
Spontaneous (n=280)	52/246 (21)	38/223 (17)	40/190 (21)	10/206 (5)
Induction (n=288)	132/278 (47)	51/263 (19)	88/242 (36)	8/233 (3)

POSTPRINT VERSION

Elective CS (n=371)	241/350 (69)	76/307 (25)	169/281 (60)	14/276 (5)
Missing (n=16)	4/13 (31)	2/3 (67)	1/7 (14)	0/6 (0)
Delivery				
Spontaneous head (n=423)	125/404 (31)	68/372 (18)	98/335 (29)	13/331 (4)
Elective CS (n=411)	267/388 (69)	84/345 (24)	178/310 (57)	16/313 (5)
Emergency CS (n=48)	17/44 (39)	10/42 (24)	15/35 (43)	1/36 (3)
Other (n=29)	8/29 (28)	2/28 (7)	4/24 (17)	2/27 (7)
Missing (n=44)	12/22 (55)	3/9 (33)	3/16 (19)	0/14 (0)
Offspring gender				
Girl (n=423)	209/404 (52)	82/374 (22)	150/346 (43)	8/335 (2)
Boy (n=435)	191/406 (47)	77/383 (20)	142/353 (40)	23/366 (6)
Missing (n=97)	29/77 (38)	8/39 (21)	6/21 (29)	1/20 (5)
Obstetrical complications reported				
No (n=744)	295/684 (43)	105/602 (17)	207/541 (38)	23/540 (4)
Yes (n=211)	134/203 (66)	62/194 (32)	91/179 (51)	9/181 (5)
PPROM reported				
No (n=862)	353/796 (44)	141/711 (20)	254/640 (40)	27/639 (4)
Yes (n=93)	76/91 (84)	26/85 (31)	44/80 (55)	5/82 (6)
Gestational age at birth				
<32 weeks (n=59)	-	21/52 (40)	48/52 (92)	4/50 (8)
32-36 weeks (n=370)	-	71/334 (21)	201/304 (66)	14/294 (5)
≥37 weeks (n=458)	-	75/398 (19)	42/345 (12)	13/345 (4)
Missing (n=68)	-	0/12 (0)	7/19 (37)	1/32 (3)
SGA				
No (n=629)	294/617 (48)	-	201/522 (39)	21/517 (4)
Yes (n=167)	92/167 (55)	-	79/146 (54)	9/146 (6)
Missing (n=159)	43/103 (42)	-	18/52 (35)	2/58 (3)
NICU admission				
No (n=422)	107/410 (26)	67/388 (17)	-	15/388 (4)
Yes (n=298)	249/291 (86)	79/280 (28)	-	14/257 (5)
Missing (n=235)	73/186 (39)	21/128 (16)	-	3/76 (4)

SGA, small-for-gestational-age; NICU, neonatal intensive care unit.

^a The different congenital malformations are listed in Table A12 of the Appendix

Table A12. Reported congenital anomalies: in 721 neonates the presence or absence of malformations was reported.

Treatment during pregnancy	Major malformation, n=15, 2 % Minor malformation, n=17, 2%
Chemotherapy	Hip subluxation (n=1) Hypospadias (n=1) Patent foramen ovale or ASD II (n=1) Two little muscular VSD (n=1) Accessory ear tag (n=1) Pectus Excavatum (n=1)
Chemotherapy + Surgery (1 unknown)	Anorectal atresia (n=1) Cleft uvula (n=1) Hypospadias (n=1) Schizis palatum molle (n=1) Unilateral kidney agenesis (n=1) Hemihypertrophy of the legs (n=1) Limb abnormalities unspecified (n=1) Syndactyly (n=1) Talipes equinovarus (n=1) Ulnar polydactyly (n=1)
Chemotherapy + Radiotherapy	Syndactyly (n=1)
Chemotherapy + Surgery + Radiotherapy	Doubled cartilage ring in both ears (n=1)
Surgery (1 unknown)	Hypospadias, left foot malformation and missing left little finger (n=1) Multicystic kidney (n=1) VSD (n=1) Syndactyly (n=1) Talipes equinovarus (n=1)
Radiotherapy	-
Surgery + Radiotherapy	-
Targeted treatment	-
Chemotherapy + Radiotherapy + Targeted treatment	VSD, unilateral kidney agenesis (n=1)
No treatment	Hip subluxation (n=1) VSD (3mm), ASD (5mm), open duct of Botalli (1mm) (n=1) Atrial septal aneurysm (n=1) Congenital laryngomalacia (n=1) Dolichocephaly (n=1) Plagiocephaly (n=2) Talipes equinovarus (n=1)

ASD, atrial septal defect; VSD, ventricular septal defect

Malformations are defects of organs or body parts due to an intrinsically abnormal developmental process. In this process, a structure is not formed, is partially formed, or is formed in an abnormal fashion. Major malformations are those that have medical and/or social implications. A major malformation is defined as one that is incompatible with survival, such as anencephaly; or one requiring major surgery for correction, such as cleft palate or congenital heart disease; or one producing major dysfunction (e.g., mental retardation). Minor malformations have mostly cosmetic significance. They rarely are medically significant or require surgical intervention. They represent part of the normal variation in the general population. (Definition according to Eurocat; www.eurocat-network.eu) Major malformations are shown in bold.

2.5 Multiple logistic regression analysis.

Table A13. Model coefficients and standard errors for the regression models presented in the main text.

	PPROM/preterm contractions	Small-for-gestational-age (SGA)	Neonatal intensive care unit (NICU) admission
Covariate	Coefficient (SE)	Coefficient (SE)	Coefficient (SE)
Malignancy			
Breast cancer	Reference	Reference	Reference
Cervical cancer	-0.30 (0.52)	-0.29 (0.37)	0.80 (0.32)
Lymphoma	0.21 (0.47)	0.15 (0.41)	0.04 (0.34)
Ovarian cancer	-0.51 (0.69)	-0.93 (0.52)	-0.50 (0.42)
Leukaemia	0.90 (0.57)	-0.39 (0.56)	0.24 (0.44)
Gastro-intestinal cancer	-1.11 (0.91)	-0.22 (0.52)	1.96 (0.47)
Melanoma	-0.27 (0.72)	-0.11 (0.57)	-1.01 (0.54)
Thyroid cancer	-0.65 (0.91)	-0.32 (0.65)	-1.98 (0.96)
Other malignancies	-0.82 (0.56)	-0.20 (0.41)	0.35 (0.34)
Period of diagnosis			
Before 2005	Reference	Reference	Reference
2005-2009	-0.22 (0.31)	-0.27 (0.27)	-0.32 (0.21)
2010-2016	-0.26 (0.30)	0.04 (0.26)	-0.60 (0.22)
Age at diagnosis (per 5 years)	0.08 (0.12)	0.31 (0.11)	-0.02 (0.09)
Diagnosis in 3 rd trimester	-0.45 (0.30)	-0.24 (0.25)	0.12 (0.19)
Systemic disease	0.36 (0.36)	0.62 (0.30)	0.13 (0.27)
Chemotherapeutic agents			
Alkylating	0.70 (0.46)	0.73 (0.44)	-0.13 (0.33)
Anthracyclines	0.10 (0.49)	-0.69 (0.45)	0.19 (0.34)
Antimetabolite	-0.12 (0.34)	0.22 (0.30)	0.03 (0.27)
Taxanes	0.10 (0.38)	0.73 (0.32)	0.86 (0.30)
Platinum	0.83 (0.54)	1.14 (0.39)	0.51 (0.39)
Other	0.39 (0.46)	0.85 (0.41)	0.49 (0.37)
Abdominal/cervical surgery	-0.87 (0.52)	0.27 (0.35)	-1.20 (0.30)

Figure A2. Estimated small-for-gestational age (SGA) rates by tumour group for an average patient. These predictions were based on the multiple logistic regression model for SGA, using average values were used for the other covariates.




Figure A3. Estimated neonatal intensive care unit (NICU) admission rates by tumour group for an average patient. These predictions were based on the multiple logistic regression model for SGA, using average values were used for the other covariates.




Figure A4. Estimated preterm prelabour rupture of membrane (PPROM) and/or preterm contraction rates by tumour group for an average patient. These predictions were based on the multiple logistic regression model for SGA, using average values were used for the other covariates.




Table A14. Results from the sensitivity analysis presenting multiple regression analysis based on complete cases. For preterm prelabour rupture of membranes (PPROM)/preterm contractions, we analysed singleton stillbirths and live births, for the neonatal complications we analysed singleton live births.

Covariate	PPROM/preterm contractions, N=874 (90% of 969)		Small-for-gestational-age, N=751 (79% of 955)		Neonatal intensive care unit admission, N=679 (71% of 955)	
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Malignancy		0.11		0.78		<0.0001
Breast cancer	Reference		Reference		Reference	
Cervical cancer	0.47 (0.15-1.45)		0.84 (0.39-1.79)		2.12 (1.11-4.03)	
Lymphoma	1.20 (0.47-3.08)		1.32 (0.59-2.95)		1.13 (0.53-2.38)	
Ovarian cancer	0.31 (0.06-1.53)		0.44 (0.16-1.24)		0.57 (0.24-1.37)	
Leukaemia	1.96 (0.63-6.07)		0.69 (0.24-1.96)		0.81 (0.32-2.04)	
Gastro-intestinal cancer	0.25 (0.04-1.54)		0.82 (0.30-2.26)		5.98 (2.30-15.5)	
Melanoma	0.41 (0.07-2.30)		1.01 (0.33-3.16)		0.36 (0.12-1.09)	
Thyroid cancer	0.48 (0.08-2.86)		0.71 (0.20-2.54)		0.17 (0.03-1.00)	
Other malignancies	0.30 (0.08-1.08)		0.86 (0.38-1.95)		2.36 (1.18-4.72)	
Period of diagnosis			0.52			
Before 2005	Reference	Reference		Reference		
2005-2009	0.69 (0.37-1.31)	0.76 (0.44-1.32)		0.67 (0.42-1.08)		
2010-2016	0.73 (0.39-1.35)		1.11 (0.66-1.85)	0.53 (0.33-0.84)		
Age at diagnosis (per 5 years)	1.11 (0.87-1.40)	0.42	1.36 (1.11-1.66)	0.0022	0.96 (0.80-1.15)	0.63
Diagnosis in 3 rd trimester	0.61 (0.33-1.12)	0.11	0.76 (0.47-1.24)	0.27	1.16 (0.77-1.74)	0.49
Systemic disease	1.49 (0.73-3.04)	0.29	2.04 (1.16-3.60)	0.014	1.76 (1.01-3.07)	0.040
Chemotherapeutic agents		0.036 ^a		0.00023 ^a		0.022 ^a
Alkylating	1.78 (0.69-4.59)		2.04 (0.87-4.83)		0.78 (0.38-1.63)	
Anthracyclines	1.09 (0.40-3.01)		0.54 (0.22-1.35)		1.24 (0.58-2.64)	
Antimetabolite	0.93 (0.48-1.80)		1.25 (0.70-2.24)		1.07 (0.62-1.85)	
Taxanes	1.18 (0.55-2.53)		2.05 (1.09-3.86)		2.75 (1.47-5.16)	
Platinum	3.47 (1.09-11.0)		2.78 (1.26-6.17)		1.33 (0.59-3.00)	
Other	1.68 (0.67-4.19)		2.02 (0.88-4.66)		1.42 (0.63-3.20)	
Abdominal/cervical surgery	0.56 (0.20-1.57)	0.27	1.30 (0.68-2.48)	0.42	0.30 (0.15-0.57)	0.00011

^a Joint test of the six chemotherapeutic agent variables.

2.6 Changes in 20 years of treatment in pregnant cancer patients.

Table A15. Differences in treatment and obstetrical outcome between patients diagnosed before 2005, between 2005-2009 and 2010-2016.

Variable	Period of diagnosis, n/N (%)				Average change every 5 calendar years (95% CI)
	<2005	2005-2009	2010-2016	Total	
All patients (n=1170)					
Age at diagnosis (years)	32 (28-36)	33 (29-36)	33 (29-36)	32 (29-36)	+0.3 (0.0-0.7)
Malignancy					
Breast cancer	91/257 (35)	151/376 (40)	220/537 (41)	462/1170 (39)	RR 1.04 (0.96-1.12)
Cervical cancer	38/257 (15)	44/376 (12)	65/537 (12)	147/1170 (13)	RR 0.94 (0.80-1.10)
Lymphoma	24/257 (9)	38/376 (10)	51/537 (9)	113/1170 (10)	RR 0.95 (0.79-1.13)
Ovarian cancer	29/257 (11)	29/376 (8)	30/537 (6)	88/1170 (8)	RR 0.79 (0.63-0.98)
Leukaemia	15/257 (6)	20/376 (5)	33/537 (6)	68/1170 (6)	RR 0.99 (0.78-1.27)
Gastro-intestinal cancer	13/257 (5)	9/376 (2)	27/537 (5)	49/1170 (4)	RR 1.31 (0.91-1.90)
Melanoma	13/257 (5)	14/376 (4)	19/537 (4)	46/1170 (4)	RR 0.89 (0.66-1.19)
Thyroid cancer	1/257 (<1)	15/376 (4)	21/537 (4)	37/1170 (3)	RR 1.65 (1.11-2.43)
Brain cancer	4/257 (2)	5/376 (1)	12/537 (2)	21/1170 (2)	RR 0.97 (0.62-1.51)
All other	29/257 (11)	51/376 (14)	59/537 (11)	139/1170 (12)	RR 1.00 (0.85-1.17)
Systemic disease	58/249 (23)	73/362 (20)	101/514 (20)	232/1125 (21)	RR 0.91 (0.80-1.02)
Treatment during pregnancy					
No treatment	111/257 (43)	122/376 (32)	158/537 (29)	391/1170 (33)	RR 0.84 (0.78-0.91)
Any treatment	146/257 (57)	254/376 (68)	379/537 (71)	779/1170 (67)	RR 1.10 (1.05-1.15)
Surgery	99/257 (39)	154/376 (41)	201/537 (37)	454/1170 (39)	RR 0.99 (0.92-1.07)
Chemotherapy	63/257 (25)	132/376 (35)	234/537 (44)	429/1170 (37)	RR 1.31 (1.20-1.43)
Radiotherapy	10/257 (4)	10/376 (3)	9/537 (2)	29/1170 (2)	RR 0.67 (0.47-0.96)
Targeted or anti-hormonal therapy	1/257 (<1)	10/376 (3)	22/537 (4)	33/1170 (3)	RR 2.10 (1.34-3.30)
Other therapy ^a	11/257 (4)	21/376 (6)	20/537 (4)	52/1170 (4)	RR 0.85 (0.65-1.11)
All patients with chemotherapy (n=429)					
GA at last chemotherapy cycle (days)	215 (193-233)	225 (210-240)	230 (208-242)	226 (207-239)	+2.6 (-1.1-6.3)
All patients with solid malignancies except brain cancers (n=1036)					
Disease stage					
I	90/217 (41)	119/313 (38)	160/459 (35)	369/989 (37)	RR 0.96 (0.88-1.04)
II	61/217 (28)	114/313 (36)	161/459 (35)	336/989 (34)	RR 1.06 (0.97-1.17)
III	36/217 (17)	49/313 (16)	80/459 (17)	165/989 (17)	RR 1.00 (0.86-1.16)
IV	30/217 (14)	31/313 (10)	58/459 (13)	119/989 (12)	RR 0.95 (0.80-1.14)
All singleton pregnancies (n=1107)					
Live birth	199/242 (82)	306/347 (88)	450/500 (90)	955/1089 (88)	RR 1.04 (1.01-1.06)
Miscarriage	8/242 (3)	5/347 (1)	6/500 (1)	19/1089 (2)	RR 0.62 (0.39-0.99)
Termination of pregnancy	27/242 (11)	30/347 (9)	38/500 (8)	95/1089 (9)	RR 0.85 (0.70-1.03)
Stillbirth (excl. died w/ mother)	7/242 (3)	4/347 (1)	3/500 (1)	14/1089 (1)	RR 0.48 (0.29-0.79)
All singleton live and stillbirths (n=969)					
PPROM	20/206 (10)	31/310 (10)	47/453 (10)	98/969 (10)	RR 0.97 (0.80-1.18)
Any obstetrical complication	44/206 (21)	64/310 (21)	117/453 (26)	225/969 (23)	RR 1.05 (0.93-1.19)
All singleton live births (n=955)					
Preterm live birth	97/180 (54)	143/280 (51)	186/424 (44)	426/884 (48)	RR 0.93 (0.86-0.99)
Iatrogenic preterm live births	88/180 (49)	128/280 (46)	157/424 (38)	373/884 (42)	RR 0.91 (0.84-0.98)
SGA	33/161 (20)	43/253 (17)	91/382 (24)	167/796 (21)	RR 1.16 (0.99-1.35)
NICU	73/147 (50)	93/226 (41)	132/347 (38)	298/720 (41)	RR 0.91 (0.83-0.99)
Congenital malformations	12/129 (9)	9/228 (4)	11/364 (3)	32/721 (4)	RR 0.62 (0.44-0.88)
Low Apgar	2/133 (2)	5/232 (2)	11/358 (3)	18/723 (2)	RR 1.00 (0.62-1.62)

RR, relative risk; CI, confidence interval.

Statistics shown are median (interquartile range) for continuous variables, and n/N (%) for categorical variables. Missing values are excluded, hence the denominator is always shown.

^a Only interferon.

2.7 Cohorts of cancer during pregnancy in the literature.

Table A16. General overview of articles on cohorts of cancer during pregnancy containing over 50 patients.

Year	Authors	No. of patients	Years of inclusion	Type of study	Countries	Malignancy	Management given during pregnancy	Pregnancy outcome	Neonatal outcome w/o SGA	SGA
2017	de Haan et al. ⁵	60	1994-2015	Retrospective cohort	Belgium, Czech Republic, Denmark, Italy, the Netherlands, Poland	Melanoma	NT: 7 (11%) S: 49 (82%) RT: 1 (2%) S + CT: 1 (2%) S + RT: 2 (3%)	TOP: 3 (5%) SB: 1 (2%) LB: 49 (84%) - 9 (18%) Preterm - 17 (40%) CS	No congenital anomalies or neonatal deaths	Non-CT exposed: 2 (4%)
2016	Lu et al. ⁶	984	1973-2012	Population based retrospective cohort	Sweden	Multiple	Not mentioned	Increased SGA related stillbirth (IRR 4.9, 95% CI 2.2 – 11.0) Increased preterm birth (IRR 5.8, 95% CI 5.3 – 6.5) - Mainly iatrogenic Increased CS rate (40% vs. 12%)	Increased neonatal mortality (IRR 2.7, 95% CI 1.3 – 5.6) - 89% prematurity related	Increased preterm SGA (RR 3.0, 95% CI 2.1 – 4.4) - Mainly haematological and ovarian cancers No increased term SGA (RR 1.0, 95% CI 0.7 – 1.3)
2016	Garofalo et al. ⁷	60	2001-2016	Single centre retrospective cohort	Italy	Multiple	NT: 24 (40%) S: 14 (23%) CT: 12 (20%) S + CT: 10 (17%)	Miscarriage: 1 (2%) SB: 1 (2%) LB: 58 - 49 (83%) preterm birth - 52 (85%) CS	Congenital malformations: 3 (5%) NICU: 22 (35%)	32% (in both CT and non-CT exposed group)
2016	Shim et al.	87	1995-2013	Retrospective cohort	South Korea	Multiple	NT: 63 (73%) S: 10 (11%) CT: 8 (9%) S + CT: 6 (7%)	Miscarriage: 1 (1%) TOP: 18 (21%) LB: 68 (78%): - 34 (50%) overall preterm - 25 (29%) iatrogenic preterm - 40 (59%) CS	Of the preterm babies: - NICU: 24 (71%) - 3 (9%) neonatal deaths	Not mentioned
2015	Amant et al. ⁸	129	2005-2015	Prospective cohort	Belgium, Czech Republic,	Multiple	NT: 14 (11%) S: 13 (10%) CT: 41 (32%) RT: 1 (1%)	79 (61%) preterm deliveries	No increase in congenital malformations	No overall increase (22% vs. 15%, p=0.16)

					Italy, the Netherlands		OT: 2 (2%) S + CT: 48 (37%) S + RT: 3 (2%) CT + RT: 3 (2%) S + CT + RT: 4 (3%)			
2015	Nazer et al. ⁹	179	2003-2011	Population based retrospective cohort	Canada	Ovarian	Not mentioned	Increased risk of CS (OR 5.92, 95% CI 4.17-8.41) Increased risk of prematurity (OR 2.24, 95% CI 1.48 – 3.42) No increased risk of PPROM or stillbirth	Not mentioned	No increased risk
2015	El-Messidi et al. ¹⁰	427	2003-2011	Population based retrospective cohort	Canada	Non-Hodgkin lymphoma	Not mentioned	Increase risk of CS (OR 1.37, 95% CI 1.13 – 1.67) Increased risk of prematurity (OR 2.50, 95% CI 1.94 – 3.22) No increased risk of IOL Increased risk of stillbirth (OR 2.71, 95% CI 1.12 – 6.55)	No increased risk of congenital malformations	No increased risk
2015	Bannister-Tyrrell et al. ¹¹	195	1994-2008	Population based retrospective cohort	Australia	Melanoma	Not mentioned	No increased risk of still birth, planned birth, CS, prematurity	Not mentioned	No increased risk 75% higher odds on LGA
2015	El-Messidi et al. ¹²	638	2003-2011	Population based retrospective cohort	Canada	Hodgkin lymphoma	Not mentioned	Increased risk of prematurity (OR 1.93, 95% CI 1.53 – 2.42) No increased risk of CS or IOL	No increased risk of congenital malformations or neonatal death	No increased risk
2014	Murthy et al. ^{a 13}	81	1992-2010	Single centre prospective cohort	USA	Breast	CT: 81 (100%)	28 (35%) premature deliveries 33% CS delivery	No increased risk of congenital malformations (n=3) NICU: 9 (14%)	Not mentioned
2013	Evens et al. ¹⁴	90	1999-2011	Retrospective cohort	USA	Lymphoma	NT: 34 (38%) CT: 31 (34%) RT: 5 (6%) OT: 1 (1%)	TOP: 6 (7%) LB: 84 (93%): - 30% Iatrogenic prematurity	NICU: 11%, no difference between antenatal and deferred therapy	No difference in birth weight between antenatal and deferred therapy

							CT + RT: 3 (3%) CT + OT: 14 (16%) CT + RT + OT: 1 (1%) UNK: 1 (1%)	- 14% Spontaneous prematurity No difference in PPRM or other obstetrical complications 33% CS rate	Congenital malformations: 2 (2%) (both in patients with antenatal CT, in second trimester)	Trent to difference in SGA but NS (41% vs. 9%, p=0.09)
2012	Lee et al. ¹⁵	499	1994-2008	Population based retrospective cohort	Australia	Multiple	Not mentioned	Increased risk of IOL (aOR 1.27, 95% CI 1.03 – 1.56) Increased risk of CS (aOR 2.08, 95% CI 1.70 – 2.54) Increased risk of iatrogenic prematurity (aOR 11.53, 95% CI 8.81 – 15.11) But no increased risk of spontaneous prematurity	No increased risk of perinatal death	No increased risk Increased risk LGA (aOR 1.47, 95% CI 1.14 81 – 1.89)
2012	Loibl et al. ^{a16}	447	2003-2011	Retrospective cohort	Multiple	Breast	Of 413 early stage: NT: 99 (24%) S: 100 (24%) CT: 118 (29%) S + CT: 79 (19%) UNK: 17 (4%)	Miscarriage/TOP: 51 (11%) SB: 3 (1%) UNK: 11 (2%) LB: 382 (86%) - 51% preterm delivery - 46% CS Symptoms of preterm delivery higher in CT group (p=0.012)	Neonatal deaths: 2 (1%) (non-treatment related) Side effects, malformations or new-born complications: 40 (10%) - More common in preterm delivered babies (16% vs. 5%, p=0.0002) - More common in CT exposed babies (15% vs. 4%, p=0.00045)	No difference in overall SGA (9% vs. 4%, p=0.10) Increase in CT related SGA (p=0.018)
2012	Abdel-Hady el et al. ¹⁷	118	2003-2011	Prospective cohort	Egypt	Multiple	NT: 44 (37%) S: 13 (11%) CT: 61 (52%)	TOP: 26 (22%) LB: 92 (78%) - 18 iatrogenic prematurity	No difference between CT exposed and healthy premature control group in: - Birth weight - Neonatal survival - NICU admission - Congenital anomalies	No difference between CT exposed and healthy premature control group
2012	Amant et al. ^{a18}	68	1994-2011	Prospective cohort study	Belgium, Czech Republic, the Netherlands	Multiple	CT: 34 (50%) S + CT: 27 (40%) CT + RT: 1 (1%)	45 (66%) premature deliveries	Congenital malformations: 7 (10%), similar to general population	Increased rate compared to general population (21%, p=0.009)

POSTPRINT VERSION

							S +CT + RT: 6 (9%)			
2012	Avilés et al. ¹⁹	58	1975-2008	Retrospective cohort study	Mexico	Haematological	CT: 58 (100%) (first trimester)	SB: 4 (7%) LB: 54 (93%) - 4 (7%) extreme prematurity	No congenital anomalies or neonatal deaths NICU: 4 (7%) (in extreme premature born children)	10 (19%)
2012	Cardonick et al. ²⁰	109	1997-2010	Single centre retrospective cohort	USA	Breast	CT: 109 (100%)	20 (18%) overall spontaneous preterm delivery	Congenital malformations: 4 (4%), no difference between groups Neonatal deaths: 1 (1%)	7 (6%)
2010	Cardonick et al. ²¹	130 (including 6 weeks postpartum)	1996-2003	Prospective + retrospective cohort	USA	Breast	Of the LB (n=116): NT: 3 (3%) S: 9 (8%) CT: 27 (23%) S + CT: 77(66%)	Miscarriage: 6 (4%) TOP: 10 (8%) UNK: 1 (1%) LB: 113 (87%): - Mean GA at delivery: 35.8 +/- 1.9 weeks - 1 spontaneous preterm delivery - 37 (33%) CS	No increased rate of congenital malformation (4%) compared to general population	8 (10%), all CT exposed No increase compared to general population
2010	Van Calsteren et al. ²²	215	1998-2008	Retrospective cohort	Multiple	Multiple	All LB (n=180): NT: 58 (31%) S: 49 (27%) CT: 33 (18%) RT: 3 (2%) OT: 5 (3%) S + CT: 25 (14%) S + RT: 3 (2%) CT + RT: 1 (1%) S + CT + RT: 3 (2%)	Miscarriage: 5 (2%) TOP: 30 (14%) LB: 180 (84%) - 54% prematurity - 72% Induction of labour/CS In CT exposed pregnancies preterm labour was increased (12%, p=0.012)	Of all LB: - NICU: 92 (51%) - NICU reason mainly prematurity (85%) No increased rate of congenital malformations	Increase in CT exposed children (24%, p=0.001)
2010	Cardonick et al. ²³	231	1995-2008	Nationwide retrospective cohort	USA	Multiple	CT: 152 (66%) UNK: 79 (34%)	TOP: 12 (5%) In CT exposed pregnancies (n=157): - SB: 1 (1%) - 9 (6%) Spontaneous prematurity No difference in mean GA at delivery between CT and non-CT exposed pregnancies:	No increased rate in CT group of: - Congenital malformations: 6 (4%) - Neonatal deaths: 1 (1%)	No increased rate in CT vs. non-CT (8% vs. 7%)

								35.8 +/- 2.8 weeks vs. 36.5 +/- 3.3 weeks		
2006	Hahn et al. ^{a24}	57	1992-	Single centre cohort	USA	Breast	CT: 19 (33%) S + CT: 38 (67%)	No miscarriage or SB Increase of 12% CS rates (40% vs. 28%) Prematurity not mentioned	No perinatal deaths Congenital malformations: 1 (2%) (Down syndrome)	Not mentioned
2005	Dalrymple et al. ²⁵	136	1991-1999	Population based retrospective cohort	USA	Cervix	Not mentioned	Increased risk of CS (OR 3.7, 95% CI 2.6 – 5.2) Increased risk of prematurity (OR 4.7, 95% CI 3.2 – 6.7), both spontaneous and iatrogenic Increased risk of still birth (OR 5.5, 95% CI 2.0 – 14.8)	Increased risk of neonatal admission (OR 5.2, 95% CI 3.6 – 7.5)	Increased risk of SGA (OR 5.5, 95% CI 3.7 – 8.1) Increased risk for extreme SGA (OR 6.9, 95% CI 3.7 – 12.8)
2005	Yasmeen et al. ²⁶	129	1991-1999	Retrospective population matched cohort	USA	Thyroid	NT: 33 (26%) S: 96 (74%)	No increased risk of prematurity or CS	No increased risk of neonatal death	No increased risk
2005	O'Meara et al. ²⁷	145	1991-1999	Population based retrospective cohort	USA	Melanoma	S: 141 (97%) UNK: 4 (3%)	No increased risk compared to healthy controls on: - SB - Prematurity - CS	No increased risk compared to healthy controls on: - NICU admission - Neonatal death	No increased risk compared to healthy controls
2000	Ibrahim et al. ²⁸	72	1992-1996	Retrospective matched cohort	Saudi Arabia	Breast	NT: 55 (76%) S: 10 (14%) S + CT: 7 (10%)	TOP: 34 (47%) LB: 38 (53%), all spontaneous vaginally delivered	No congenital malformations	Not mentioned

NT, no treatment during pregnancy; S, surgery during pregnancy; CT, chemotherapy during pregnancy; RT, radiotherapy during pregnancy; OT, other treatment during pregnancy; SB, still birth; LB, live birth; CS, caesarean section; SGA, small-for-gestational-age, NICU, neonatal intensive care unit.

^aData from the same research groups or medical centres may be used in different studies.

Reported numbers and interpretation of numbers are as reported in the studies.

3 Participating investigators

Table A17. List of investigators per institution.

INCIP member	Hospital	City	Country
Achtari, C.	University Hospital of Lausanne	Lausanne	Switzerland
Alonso Salvador, S.	MD Anderson Cancer Center	Madrid	Spain
Altintas, S.	Antwerp University Hospital	Antwerp	Belgium
Amant, F.	University Hospital Leuven	Leuven	Belgium
Baljewicz-Nowak, M.	University Hospital of Krakow, Macierzynstwo Medical Center	Krakow	Poland
Benedicic, C.	University Hospital of Obstetrics and Gynaecology	Graz	Austria
Bjelic-Radisic, V.	University Hospital of Obstetrics and Gynaecology	Graz	Austria
Boere, I.	Erasmus Medical Center Rotterdam	Rotterdam	the Netherlands
Cardonick, E.	Cooper University Hospital	Camden	United States of America
Ceppi, L.	San Gerardo Hospital	Monza	Italy
Dahl Steffensen, K.	Vejle Hospital	Vejle	Denmark
Fountzilias, G.	Papageorgiou Hospital	Pavlos Melas	Greece
Fruscio, R.	San Gerardo Hospital	Monza	Italy
Fumagalli, M.	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano	Milan	Italy
Groot, C. de	VU University Medical Center	Amsterdam	the Netherlands
Haidopoulos, D.	Alexandra General Hospital	Athens	Greece
Halaska, M.	3rd Medical Faculty Charles University	Prague	Czech Republic
Hasenburg, A.	University Hospital of Freiburg	Freiburg	Germany
Heredia, F.	Hospital Las Higueras de Talcahuano	Talcahuano	Chile
Klaritsch, P.	University Hospital of Obstetrics and Gynaecology	Graz	Austria
Kolawa, W.	University Hospital of Krakow, Macierzynstwo Medical Center	Krakow	Poland
Koskas, M.	Bichat – Claude-Bernard Hospital	Paris	France
Lang, U.	University Hospital of Obstetrics and Gynaecology	Graz	Austria
Lampka, E.	Maria Sklodowska-Curie Memorial Cancer Center	Warsaw	Poland
Lok, C.	Antoni van Leeuwenhoek - Netherlands Cancer Institute	Amsterdam	the Netherlands
Mangili, G.	San Raffaele Hospital Milan	Milan	Italy
Masturzo, B.	Mauriziano	Turin	Italy
Mhallem, M.	Cliniques Universitaires St-Luc U.C.L.	Brussels	Belgium
Ottevanger, N.	Radboud University Nijmegen Medical Center	Nijmegen	the Netherlands
Painter, R.	Academical Medical Center Amsterdam	Amsterdam	the Netherlands
Parokonnaya, A.	N.N. Blochin Cancer Research Center	Moscow	Russia
Pavlidis, N.	Ioannina University Hospital	Ioannina	Greece
Peccatori, F.	European Institute of Oncology	Milan	Italy
Pitynski, K.	University Hospital of Krakow, Macierzynstwo Medical Center	Krakow	Poland
Raut, J.	Royal Derby Hospital	Derby	Great Britain
Schröder, C.	University Medical Center Groningen	Groningen	the Netherlands
Shmakov, R.	Research Center for Obstetrics	Moscow	Russia
Skrzypczyk-Ostaszewicz, A.	Maria Sklodowska-Curie Memorial Cancer Center	Warsaw	Poland
Sosinska, K.	Regional Oncology Center	Gdansk	Poland
Witteveen, E.	University Medical Center Utrecht	Utrecht	the Netherlands
Zapardiel, I.	La Paz University Hospital	Madrid	Spain
Zola, P.	University of Turin	Turin	Italy
	Other non-academic hospitals in the Netherlands	-	the Netherlands

4 References.

1. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med* 2011; **30**(4): 377-99.
2. Buuren Sv, Groothuis-Oudshoorn K. Mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software* 2011; **45**(3): 1-67.
3. Sullivan TR, Salter AB, Ryan P, Lee KJ. Bias and Precision of the "Multiple Imputation, Then Deletion" Method for Dealing With Missing Outcome Data. *Am J Epidemiol* 2015; **182**(6): 528-34.
4. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. *Stat Med* 2010; **29**(28): 2920-31.
5. de Haan J, Lok CA, de Groot CJ, et al. Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma. *Melanoma Res* 2017.
6. Lu D, Ludvigsson JF, Smedby KE, et al. Maternal Cancer During Pregnancy and Risks of Stillbirth and Infant Mortality. *J Clin Oncol* 2017; **35**(14): 1522-9.
7. Garofalo S, Degennaro VA, Salvi S, et al. Perinatal outcome in pregnant women with cancer: are there any effects of chemotherapy? *Eur J Cancer Care (Engl)* 2016.
8. Amant F, Vandembroucke T, Verhecke M, et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. *N Engl J Med* 2015; **373**(19): 1824-34.
9. Nazer A, Czuzoj-Shulman N, Oddy L, Abenhaim HA. Incidence of maternal and neonatal outcomes in pregnancies complicated by ovarian masses. *Arch Gynecol Obstet* 2015; **292**(5): 1069-74.
10. El-Messidi A, Patenaude V, Abenhaim HA. Incidence and outcomes of women with non-Hodgkin's lymphoma in pregnancy: a population-based study on 7.9 million births. *J Obstet Gynaecol Res* 2015; **41**(4): 582-9.
11. Bannister-Tyrrell M, Roberts CL, Hasovits C, Nippita T, Ford JB. Incidence and outcomes of pregnancy-associated melanoma in New South Wales 1994-2008. *Aust N Z J Obstet Gynaecol* 2015; **55**(2): 116-22.
12. El-Messidi A, Patenaude V, Hakeem G, Abenhaim HA. Incidence and outcomes of women with Hodgkin's lymphoma in pregnancy: a population-based study on 7.9 million births. *J Perinat Med* 2015; **43**(6): 683-8.
13. Murthy RK, Theriault RL, Barnett CM, et al. Outcomes of children exposed in utero to chemotherapy for breast cancer. *Breast Cancer Res* 2014; **16**(6): 500.
14. Evens AM, Advani R, Press OW, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. *J Clin Oncol* 2013; **31**(32): 4132-9.
15. Lee YY, Roberts CL, Dobbins T, et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study. *BJOG* 2012; **119**(13): 1572-82.
16. Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study. *The Lancet Oncology* 2012; **13**(9): 887-96.
17. Abdel-Hady el S, Hemida RA, Gamal A, El-Zafarany M, Toson E, El-Bayoumi MA. Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy. *Arch Gynecol Obstet* 2012; **286**(2): 283-6.
18. Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. *The Lancet Oncology* 2012; **13**(3): 256-64.
19. Avilés A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. *Clin Lymphoma* 2001; **2**(3): 173-7.
20. Cardonick E, Gilmandyar D, Somer RA. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. *Obstet Gynecol* 2012; **120**(6): 1267-72.
21. Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. *Cancer J* 2010; **16**(1): 76-82.
22. Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. *J Clin Oncol* 2010; **28**(4): 683-9.
23. Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. *Am J Clin Oncol* 2010; **33**(3): 221-8.
24. Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. *Cancer* 2006; **107**(6): 1219-26.
25. Dalrymple JL, Gilbert WM, Leiserowitz GS, et al. Pregnancy-associated cervical cancer: obstetric outcomes. *J Matern Fetal Neonatal Med* 2005; **17**(4): 269-76.
26. Yasmeen S, Cress R, Romano PS, et al. Thyroid cancer in pregnancy. *Int J Gynaecol Obstet* 2005; **91**(1): 15-20.
27. O'Meara AT, Cress R, Xing G, Danielsen B, Smith LH. Malignant melanoma in pregnancy. A population-based evaluation. *Cancer* 2005; **103**(6): 1217-26.

28. Ibrahim EM, Ezzat AA, Baloush A, Hussain ZH, Mohammed GH. Pregnancy-associated breast cancer: a case-control study in a young population with a high-fertility rate. *Med Oncol* 2000; **17**(4): 293-300.